



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/52, C07K 14/78, 19/00, A61K 38/17	A2	(11) International Publication Number: WO 00/44908 (43) International Publication Date: 3 August 2000 (03.08.00)
(21) International Application Number: PCT/US00/02482 (22) International Filing Date: 1 February 2000 (01.02.00) (30) Priority Data: 60/118,053 1 February 1999 (01.02.99) US (71) Applicant (for all designated States except US): BETH ISRAEL DEACONESS MEDICAL CENTER [US/US]; 330 Brookline Avenue, Boston, MA 02215 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): LAWLER, John, W. [US/US]; 6 Gale Road, Swampscott, MA 01907 (US). (74) Agents: HOGLE, Doreen, M. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: COMP/TSP-1, COMP/TSP-2 AND OTHER CHIMERIC PROTEINS (57) Abstract <p>Tumors attract blood vessels in order to grow by a process called angiogenesis. The relative quantity of stimulators and inhibitors is an important determining factor for the initiation of angiogenesis. Thrombospondins-1 and -2 are adhesive glycoproteins that have the ability to inhibit angiogenesis. This inhibiting activity has been mapped to the type 1 repeats of TSP-1 and TSP-2. The invention includes chimeric proteins that contain anti-angiogenic portions of TSP-1, TSP-2, endostatin, angiostatin, platelet factor 4, or prolactin, linked to a portion of the N-terminal region of human cartilage oligomeric matrix protein (COMP) that allows formation of pentamers. Also described herein are the nucleic acid molecules, vectors, and host cells for expressing and producing these chimeric proteins. Further embodiments of the invention include methods to treat humans or other mammals with anti-angiogenic proteins to reduce tumor size or rate of growth. Since the type 1 repeat region of TSP-1 and TSP-2 reportedly inhibits HIV infection, chimeric proteins comprising these repeats may also be used for this purpose, as well as to inhibit angiogenesis.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

COMP/TSP-1, COMP/TSP-2 AND OTHER CHIMERIC PROTEINS

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/118,053 filed February 1, 1999, the entire teachings of which are incorporated
5 herein by reference.

BACKGROUND OF THE INVENTION

Thrombospondins are a family of calcium-binding multifunctional glycoproteins that are secreted by various cell types and are developmentally regulated components of the extracellular matrix (Bornstein, P., *FASEB J.*, 6:3290-
10 3299, 1992; Bornstein, P., *J. Cell Biol.*, 130:503-506, 1995). Among their functions are modulating cell attachment, migration and proliferation.

One member of this family, cartilage oligomeric matrix protein (COMP) is a pentamer in which multimerization appears to be directed by α -helical segments situated (in the amino acid sequence) either before or after the cysteine residues that
15 form the interchain disulfide bonds. COMP has been purified (Prochownik, E.V. *et al.*, *J. Cell Biol.* 109:843-852 (1989)). Individuals affected with pseudoachondroplasia, who have considerably shortened stature as a result of premature cessation of bone growth, have been shown to have mutations in exon 17B of the COMP protein (*Nature Genetics* 10:325-329 (1995)).

20 In vitro assays have shown that platelet thrombospondin-1 is involved in thrombosis, fibrinolysis, wound healing, inflammation, tumor cell metastasis and angiogenesis. The major form of thrombospondin secreted by platelets and endothelial cells is TSP-1. Thrombospondin-1 (TSP-1) is an angiogenesis inhibitor that decreases tumor growth. Thrombospondin- 2 (TSP-2) is a related glycoprotein
25 of similar structure and properties.

The thrombospondin type 1 repeats (TSRs; also "repeat regions" herein) have been shown to inhibit angiogenesis and HIV infection. However, other portions of the proteins have been shown to have a positive effect on endothelial cell

growth. Thrombospondin-1 and -2 are similar in terms of their molecular architecture. Thrombospondin-1 and thrombospondin-2 each have three copies of the TSR. TSP-1 and TSP-2 are trimeric molecules. Thus, each fully assembled protein contains nine TSRs.

5 Whereas TSP-1 and TSP-2 are antiangiogenic, these proteins contain other domains that have additional activities that diminish the antiangiogenic activity. The isolated TSRs are more potent inhibitors of angiogenesis than the native molecules.

 The ingrowth of new capillary networks into developing tumors is essential
10 for the progression of cancer. Thus, the development of pharmaceuticals that inhibit the process of angiogenesis is an important therapeutic goal. As pointed out in a review by Folkman (Folkman, J., *Proc. Natl. Acad. Sci. USA* 95: 9064-9066, 1998), antiangiogenic therapy has little toxicity, does not require the therapeutic agent to enter tumor cells or cross the blood-brain barrier, controls tumor growth
15 independently of growth of tumor cell heterogeneity, and does not induce drug resistance.

SUMMARY OF THE INVENTION

 The invention includes chimeric proteins comprising: (1) a chimeric protein comprising the second and third type 1 repeats of human TSP-1, and which may also
20 comprise the procollagen homology region of TSP-1; (2) a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1; (3) a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human
25 TSP-1, but not the TGF- β activation region of human TSP-1; (4) a chimeric protein comprising the multimerization domain of human COMP, the procollagen region, and the first, second, and third type 1 repeats of human TSP-1; (5) a chimeric protein comprising the three type 1 repeats of human TSP-2, and which may also comprise the procollagen homology region of TSP-2; (6) a chimeric protein comprising the
30 multimerization domain of human COMP, the first type 2 repeat of human COMP,

and the three type 1 repeats of human TSP-2; and (7) variants of any of the above having anti-angiogenic activity. The invention further includes isolated nucleic acids encoding any of the above chimeric proteins, vectors comprising these nucleic acids, and host cells comprising any of said vectors. The chimeric proteins can be
5 produced in host cells and used in methods for the treatment of a disease or medical condition characterized by abnormal or undesirable proliferation of blood vessels, such as that occurring in tumor growth.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a representation of the amino acid sequence of human TSP-1
10 (SEQ ID NO: 1). The type 1 repeats of TSP-1 are, as illustrated here, 1) amino acids 361-416; 2) amino acids 417-473; and 3) amino acids 474-530.

Figure 2 is a representation of the amino acid sequence of human TSP-2 (SEQ ID NO: 2). The type 1 repeats of TSP-2 are, as illustrated here, 1) amino acids 381-436; 2) amino acids 437-493; and 3) amino acids 494-550.

15 Figure 3 is a representation of the amino acid sequence of human COMP (SEQ ID NO: 3). The type 2 repeats of COMP are, as illustrated here, 1) amino acids 89-128; 2) amino acids 129-181; 3) amino acids 182-226; and 4) amino acids 227-268

Figures 4A and 4B together are a representation of the DNA sequence (SEQ
20 ID NO: 4) of gene encoding a human COMP/TSP-1 chimeric protein and the amino acid sequence (SEQ ID NO: 5) of a human COMP/TSP-1 chimeric protein encoded by the DNA sequence above it.

Figure 5A and 5B together are a representation of the DNA sequence (SEQ
ID NO: 6) of a gene encoding a human COMP/TSP-2 chimeric protein and the
25 amino acid sequence (SEQ ID NO: 7) of a human COMP/TSP-2 chimeric protein encoded by the DNA sequence above it.

Figure 6 is a schematic representation of a few of the chimeric protein embodiments of the invention.

Figure 7 is a graph showing tumor volume (mm^3) at 7, 14 and 21 days in the
30 experiment described in Example 3, in which mice were injected with an unaltered

(control) vector, pNeo (filled diamonds) or with an expression vector encoding COMP/TSP-1 chimeric protein (filled squares).

DETAILED DESCRIPTION OF THE INVENTION

Described herein is a protein that has the functional activity of the TSR but
5 not other activities associated with TSP-1 or TSP-2, and is assembled into a
multimeric structure. One embodiment of the invention is a chimeric protein that
comprises the TSRs from TSP-1 or TSP-2 and the multimer assembly region of
human cartilage oligomeric matrix protein (COMP), using a portion of the amino-
terminal end. Other portions of TSP-1 or TSP-2 can be incorporated into the
10 chimeric protein, such as the procollagen homology region of TSP-1 and/or TSP-2.
The last two TSRs of TSP-1 are preferably used because the first TSR has the ability
to activate transforming growth factor β (TGF- β), which stimulates tumor growth.
The COMP assembly domain spontaneously forms a 5-stranded α -helical domain,
allowing for the use of the COMP domain as a tool for pentamerization.

15 Thus, the COMP/TSP-1 construct contains the region for multimerization,
the first type 2 repeat of human COMP (construct encodes amino acids 1-128) and
the second and third TSRs of human TSP-1 (construct encodes amino acids 417-
530). See the Table for active sequences of TSP-1 (taken from chapter 2, "The
Primary Structure of the Thrombospondins" In *The Thrombospondin Gene Family*
20 (J.C. Adams *et al.*, eds.) Springer-Verlag, Heidelberg (1995)). The assembled
protein is a pentamer containing 10 copies of the TSR. Thus, COMP/TSP-1 and
COMP/TSP-2 are expected to be more active than TSP-1 and TSP-2. COMP/TSP-1
and COMP/TSP-2 are expected to be correctly folded and multimeric so that they
better mimic the natural proteins than peptides that are based on the TSR sequence.

25 The first type 2 repeat of COMP includes amino acid residues 73-130, based
on the genomic sequence. The amount of COMP sequence at the 3' end can be
increased or decreased to maximize activity. For example, two or more type 2
repeats of COMP can be included if moving the type 1 repeats of TSP-1 or TSP-2
farther out on the arms of the expressed protein increases its activity. Alternatively,
30 "spacer" sequence not naturally occurring in COMP or in TSP-1 or TSP-2 can be

added. The COMP/TSP-2 construct contains the same region of COMP and the three TSRs of human TSP-2 (construct encodes amino acids 381-550). When it is assembled to a pentamer this chimeric protein will contain 15 TSRs. Because these proteins are derived from portions of human proteins, they should not be

5 immunogenic in humans.

Table: Active Regions of Interest Within Thrombospondin-1

Domain	Sequence	Function
Procollagen homology	NGVQYRN (SEQ ID NO: 8)	Anti-angiogenesis
10 Type 1 repeats	CSVTCG (SEQ ID NO: 9)	Cell binding
	WSXWSXW (SEQ ID NO: 10)	Heparin binding
	GGWSHW (SEQ ID NO: 11)	TGF- β and Fibronectin binding
	RFK	TGF- β activation
	SPWDICSVTCGGGVQKRSR (SEQ ID NO: 12)	Anti-angiogenesis
Type 2 repeats	DVDEC(X) ₆ C(X) ₈ CENTDPGYNCLPC (SEQ ID NO: 13)	Calcium binding

In one aspect, the invention comprises polynucleotides or nucleic acid molecules that encode chimeric proteins having portions whose amino acid sequences are derived from human TSP-1. By the genomic structure, the type 1 repeats of TSP-1 are amino acid residues 359-414 (first), amino acid residues 415-473 (second), and 474-531 (third). In one case, the chimeric protein encoded by the polynucleotides of the invention comprises the second and third type 1 repeats of human TSP-1. Such a chimeric protein may also comprise the procollagen homology region and the first type 1 repeat of TSP-1. If amino acid sequences that activate TGF- β are included in the product protein, and are found to reduce anti-angiogenic activity, the RFK sequence can be mutated (to QFK, for example) to a

sequence that does not activate TGF- β , by appropriate manipulations of the nucleic acid molecule or construct encoding the chimeric proteins. In another case, the chimeric proteins encoded by the polynucleotides of the invention are variants of the immediately aforementioned chimeric protein which have activity that is similar in
5 quality and quantity (for example, plus or minus one order of magnitude in an assay) to the anti-angiogenic activity of the protein whose amino acid sequence is represented in Figures 4A and 4B. In another case, the chimeric proteins encoded by polynucleotides of the invention comprise the second and third type 1 repeats of human TSP-1, the multimerization domain of human COMP, and the first type 2
10 repeat of human COMP. In another case, the chimeric proteins encoded by the polynucleotides of the invention are variants of the immediately aforementioned chimeric protein which have activity that is similar in quality and quantity to the anti-angiogenic activity of the protein whose amino acid sequence is represented in Figures 4A and 4B.

15 In one aspect, the invention comprises polynucleotides or nucleic acid molecules that encode chimeric proteins having portions whose amino acid sequences are derived from human TSP-2. The genomic structure of the human TSP-2 gene, which would provide one way to define the boundaries of the repeats, has not been determined. In one case, the chimeric protein encoded by the
20 polynucleotides of the invention comprises the three type 1 repeats of human TSP-2. In another case, the chimeric proteins encoded by the polynucleotides of the invention are variants of the immediately aforementioned chimeric proteins which have activity that is similar in quality and quantity to the anti-angiogenic activity of the protein whose amino acid sequence is represented in Figures 5A and 5B. In
25 another case, the chimeric protein encoded by polynucleotides of the invention comprises the three type 1 repeats of human TSP-2, and the multimerization domain of human COMP. In another case, the chimeric proteins encoded by the polynucleotides of the invention are variants of the immediately aforementioned chimeric protein which have activity that is similar in quality and quantity to the
30 anti-angiogenic activity of the protein whose amino acid sequence is represented in Figures 5A and 5B.

The polynucleotides of the invention can be made by recombinant methods, can be made synthetically, can be replicated by enzymes in *in vitro* (e.g., PCR) or *in vivo* systems (e.g., by suitable host cells, when inserted into a vector appropriate for replication within the host cells), or can be made by a combination of methods. The
5 polynucleotides of the invention can include DNA and its RNA counterpart.

As used herein, "nucleic acid," "nucleic acid molecule," "oligonucleotide" and "polynucleotide" include DNA and RNA and chemical derivatives thereof, including phosphorothioate derivatives and RNA and DNA molecules having a radioactive isotope or a chemical adduct such as a fluorophore, chromophore or
10 biotin (which can be referred to as a "label"). The RNA counterpart of a DNA is a polymer of ribonucleotide units, wherein the nucleotide sequence can be depicted as having the base U (uracil) at sites within a molecule where DNA has the base T (thymidine).

Isolated nucleic acid molecules or polynucleotides can be purified from a
15 natural source or can be made recombinantly. Polynucleotides referred to herein as "isolated" are polynucleotides purified to a state beyond that in which they exist in cells. They include polynucleotides obtained by methods described herein, similar methods or other suitable methods, and also include essentially pure polynucleotides produced by chemical synthesis or by combinations of biological and chemical
20 methods, and recombinant polynucleotides that have been isolated. The term "isolated" as used herein for nucleic acid molecules, indicates that the molecule in question exists in a physical milieu distinct from that in which it occurs in nature. For example, an isolated polynucleotide may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs, and may even be purified
25 essentially to homogeneity, for example as determined by agarose or polyacrylamide gel electrophoresis or by A_{260}/A_{280} measurements, but may also have further cofactors or molecular stabilizers (for instance, buffers or salts) added.

The invention further comprises the polypeptides encoded by the isolated nucleic acid molecules of the invention. Thus, for example, the invention relates to
30 fusion proteins, comprising a portion of TSP-1 which comprises the second and third type 1 repeats, linked to a second moiety not occurring in TSP-1 as found in

nature. In an analogous manner, the invention relates also to fusion proteins, comprising TSP-2 or a functional portion thereof such as one or more repeat regions as a first moiety, linked to second moiety not occurring in TSP-2 as found in nature. The second moiety can be an amino acid, peptide or polypeptide, and can have enzymatic or binding activity of its own. The first moiety can be in an N-terminal location, C-terminal location or internal to the fusion protein. In one embodiment, the fusion protein comprises the portion of human TSP-1 described immediately above, or human TSP-2 or a portion thereof as the first moiety, and a second moiety comprising a linker sequence and an affinity ligand.

Another aspect of the invention relates to a method of producing a chimeric protein of the invention, or a variant thereof, and to expression systems and host cells containing a vector appropriate for expression of a chimeric protein of the invention. Variants of the chimeric protein include those having amino acid sequences that differ from those sequences in Figures 4A and 4B, and Figures 5A and 5B, wherein those variants have several, such as 5 to 10, 1 to 5, or 3, 2 or 1 amino acids substituted, deleted, or added, in any combination, compared to the sequences in Figures 4A and 4B and Figures 5A and 5B. In one embodiment, variants have silent substitutions, additions and deletions that do not alter the properties and activities of the chimeric protein. Variants can also be modified polypeptides in which one or more amino acid residues are modified, and mutants comprising one or more modified residues.

Proteins and polypeptides described herein can be assessed for their angiogenic activity by using an assay such as those described in Tolsma, S.S. *et al.*, *J. Cell Biol.* 122(2):497-511 (1993), one which measures the migration of bovine adrenal capillary endothelial cells in culture, and one which tests migration of cells into a sponge containing an agent to be tested for activity. A further test for angiogenesis, which can also be adapted also to test anti-angiogenesis activity, is described in Polverini, P.J. *et al.*, *Methods. Enzymol.* 198:440-450 (1991).

Cells that express such a chimeric protein or a variant thereof can be made and maintained in culture, under conditions suitable for expression, to produce protein for isolation. These cells can be procaryotic or eucaryotic. Examples of

procaryotic cells that can be used for expression (as "host cells"; "cell" including herein cells of tissues, cell cultures, cell strains and cell lines) include *Escherichia coli*, *Bacillus subtilis* and other bacteria. Examples of eucaryotic cells that can be used for expression include yeasts such as *Saccharomyces cerevisiae*,
5 *Schizosaccharomyces pombe*, *Pichia pastoris* and other lower eucaryotic cells, and cells of higher eucaryotes such as those from insects and mammals. Suitable cells of mammalian origin include primary cells, and cell lines such as CHO, HeLa, 3T3, BHK, COS, 293, and Jurkat cells. Suitable cells of insect origin include primary cells, and cell lines such as SF9 and High five cells. (See, e.g., Ausubel, F.M. *et al.*,
10 eds. *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons Inc., (containing Supplements up through 1998)).

In one embodiment, host cells that produce a recombinant chimeric protein, variant, or portions thereof can be made as follows. A gene encoding a chimeric protein described herein can be inserted into a nucleic acid vector, e.g., a DNA
15 vector, such as a plasmid, virus or other suitable replicon (including vectors suitable for use in gene therapy, such as those derived from adenovirus or others; see, for example Xu, M. *et al.*, *Molecular Genetics and Metabolism* 63:103-109, 1998) can be present in a single copy or multiple copies, or the gene can be integrated in a host cell chromosome. A suitable replicon or integrated gene can contain all or part of
20 the coding sequence for the protein or variant, operably linked to one or more expression control regions whereby the coding sequence is under the control of transcription signals and linked to appropriate translation signals to permit translation. The vector can be introduced into cells by a method appropriate to the type of host cells (e.g., transformation, electroporation, infection). For expression
25 from the gene, the host cells can be maintained under appropriate conditions (e.g., in the presence of inducer, normal growth conditions, etc.). Proteins or polypeptides thus produced can be recovered (e.g., from the cells, the periplasmic space, culture medium) using suitable techniques.

The invention also relates to isolated proteins or polypeptides encoded by
30 nucleic acids of the present invention. Isolated proteins can be purified from a natural source or can be made recombinantly. Proteins or polypeptides referred to

herein as "isolated" are proteins or polypeptides purified to a state beyond that in which they exist in cells and include proteins or polypeptides obtained by methods described herein, similar methods or other suitable methods, and also include essentially pure proteins or polypeptides, proteins or polypeptides produced by chemical synthesis or by combinations of biological and chemical methods, and recombinant proteins or polypeptides which are isolated. Thus, the term "isolated" as used herein, indicates that the polypeptide in question exists in a physical milieu distinct from the cell in which its biosynthesis occurs. For example, an isolated COMP/TSP-1 or COMP/TSP-2 chimeric protein may be purified essentially to homogeneity, for example as determined by PAGE or column chromatography (for example, HPLC), but may also have further cofactors or molecular stabilizers added to the purified protein to enhance activity. In one embodiment, proteins or polypeptides are isolated to a state at least about 75% pure; more preferably at least about 85% pure, and still more preferably at least about 95% pure, as determined by Coomassie blue staining of proteins on SDS-polyacrylamide gels.

Chimeric or fusion proteins can be produced by a variety of methods. For example, a chimeric protein can be produced by the insertion of a TSP gene or portion thereof into a suitable expression vector, such as Bluescript SK +/- (Stratagene), pGEX-4T-2 (Pharmacia), pET-15b, pET-20b(+) or pET-24(+) (Novagen). The resulting construct can be introduced into a suitable host cell for expression. Upon expression, chimeric protein can be purified from a cell lysate by means of a suitable affinity matrix (see e.g., *Current Protocols in Molecular Biology* (Ausubel, F.M. *et al.*, eds., Vol. 2, pp. 16.4.1-16.7.8, containing supplements up through Supplement 44, 1998).

Polypeptides of the invention can be recovered and purified from cell cultures by well-known methods. The recombinant protein can be purified by ammonium sulfate precipitation, heparin-Sepharose affinity chromatography, gel filtration chromatography and/or sucrose gradient ultracentrifugation using standard techniques. Further methods that can be used for purification of the polypeptide include ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction

chromatography, affinity chromatography, hydroxylapatite chromatography and high performance liquid chromatography. Known methods for refolding protein can be used to regenerate active conformation if the polypeptide is denatured during isolation or purification.

5 The method to construct genes encoding COMP/TSP-1 or COMP/TSP-2 hybrid proteins can be applied more broadly to produce polynucleotides, and vectors and host cells comprising such polynucleotides, wherein the polynucleotides encode COMP/endostatin, COMP/angiostatin, COMP/platelet factor 4, or COMP/prolactin, for example. In each case, a portion of a polynucleotide known to encode full-
10 length human endostatin, angiostatin, platelet factor 4 (GenBank Accession No. M25897) or prolactin (GenBank Accession No. V00566), can be chosen for cloning into a COMP cDNA as illustrated herein for COMP/TSP-1 and COMP/TSP-2 DNA constructs. Thus, the invention also includes COMP/endostatin, COMP/angiostatin, COMP/platelet factor 4, and COMP/prolactin chimeric proteins encoded by such
15 nucleic acid constructs. See Figure 6 for a schematic representation of the structure of COMP/endostatin.

 In addition, a portion of the endostatin, angiostatin, platelet factor 4 or prolactin coding regions, wherein that portion encodes a polypeptide having anti-angiogenic activity, can be added to or incorporated into a DNA construct encoding
20 COMP/TSP-1, such that a TSP-1-derived polypeptide and a polypeptide derived from endostatin, angiostatin, platelet factor 4 or prolactin are produced fused together in tandem on the same "arm" of the "5-armed" COMP-multimerized pentamer. Different expression constructs can be introduced into the same host cells such that two or more chimeric protein "arms" of different types (e.g.,
25 COMP/angiostatin and COMP/TSP-1 or COMP/TSP-2) are joined at the COMP multimerization domain.

 Chimeric protein antiangiogenic agents can be used, for example, after surgery or radiation to prevent recurrence of metastases, in combination with conventional chemotherapy, immunotherapy, or various types of gene therapy not
30 necessarily directed against angiogenesis.

Construction of COMP/TSP-1P Expression Vectors

Expression vectors that can be used to produce COMP/TSP-1P, a chimeric protein that includes the procollagen homology region (see Figure 6), can be produced from two distinct cDNAs. The COMP portion is identical to that in the

5 Examples described herein. For TSP-1, a new forward primer (GAT GAC GTC ACT GAA GAG AAC AAA GAG) (SEQ ID NO: 14) and the same reverse primer as described in the Examples can be used to produce a PCR product that is approximately 750 base pairs in size and has an AatII restriction endonuclease site at the 5' end and an XbaI restriction endonuclease site at the 3' end. The product codes

10 for amino acids 284-530 and includes the procollagen homology region (exons 6 and 7) and type 1 repeats. If inclusion of the TGF- β activating sequence (RFK) that is in the first type 1 repeat is found to reduce the antitumor activity, this sequence will be mutated to an inactive sequence (QFK, for example) using an oligonucleotide-directed mutagenesis kit (Amersham). The COMP/TSP-1P expression vector can be

15 constructed by cutting the PCR product with AatII and XbaI and cloning it into the COMP cDNA cut with the same enzymes. The protein can be expressed using the methods that have been described for COMP/TSP-1 and COMP/TSP-2.

Construction of COMP/Endostatin Expression Vectors

The strategy for making multimers of the TSP-1 and TSP-2 can be used to

20 make multimers of other anti-angiogenic proteins. For example, if the active region of endostatin is prepared by PCR and cloned into the COMP cDNA, a pentameric structure of endostatin can be made when this construct is expressed (O'Reilly M.D., *et al.*, *Cell* 88:277-285, (1997)). In addition, if the COMP/TSP-1 and the COMP/endostatin genes are expressed concurrently within the same cells, mixed

25 pentamers of COMP/TSP-1 and COMP/endostatin subunits are made. The mixed multimer allows simultaneous treatment with the two reagents by delivery of a single therapeutic. An additive or synergistic effect of the two agents may significantly increase the efficacy of this reagent as compared to that of each reagent alone. For example, combination therapy with angiostatin and endostatin has

30 eradicated tumors in mice (Boehm, T. *et al.*, *Nature* 390:404-407, 1997).

The cDNA for endostatin can be prepared by PCR of liver cDNA or from an isolated cDNA clone for collagen XVIII (GenBank accession no. L22548). The human endostatin cDNA can be produced by PCR with the forward primer GAT GAC GTC CAC AGC CAC CGC G (SEQ ID NO: 15) and the reverse primer GAT
5 TCT AGA CTA CTT GGA GGC AGT CAT G (SEQ ID NO: 16). The resulting PCR product is approximately 560 base pairs and encodes amino acids 1 to 184 of human endostatin (Sasaki, T., *et al.*, *EMBO J.*, 17:4249-4256, 1998). The COMP/endostatin expression vector can be constructed by cutting the PCR product with AatII and XbaI, and cloning it into cDNA cut with the same enzymes. The
10 protein can be expressed using the methods that have been described herein for COMP/TSP-1 and COMP/TSP-2. Angiostatin, as it was isolated from mice bearing Lewis lung carcinoma, includes the first four kringle domains of plasminogen (amino acids 98-440) (O'Reilly, M.S., *et al.*, *Cell* 79:315-328, 1994). It should be noted that smaller constructs that contain fewer kringle domains should also be
15 active based on published data (Griscelli, F., *et al.*, *Proc. Natl. Acad. Sci. USA* 95:6367-6372, 1998). A 16,000 dalton fragment of prolactin and platelet factor 4 have also been reported to inhibit angiogenesis (Clapp, C. *et al.*, *Endocrinology* 133:1292-1299, 1993; Gupta, S.K., *et al.*, *Proc. Natl. Acad. Sci. USA* 92:7799-7803, 1995).

20 Also included in the inventions are compositions containing, as a biological ingredient, an anti-angiogenic chimeric protein, or a variant thereof to inhibit angiogenesis in mammalian tissues, and use of such compositions in the treatment of diseases and conditions characterized by, or associated with, angiogenic activity. Such methods can involve administration by oral, topical, injection, implantation,
25 sustained release, or other delivery methods that bring one or more anti-angiogenic chimeric proteins in contact with cells whose growth is to be inhibited.

The present invention includes a method of treating an angiogenesis-mediated disease with a therapeutically effective amount of one or more anti-angiogenic chimeric proteins. Angiogenesis-mediated diseases can include, but are
30 not limited to, cancers, solid tumors, tumor metastasis, benign tumors (*e.g.*, hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic

granulomas), rheumatoid arthritis, psoriasis, ocular angiogenic diseases (*e.g.*, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis), Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, 5 hemophiliac joints, angiofibroma, and wound granulation.

"Cancer" means neoplastic growth, hyperplastic or proliferative growth or a pathological state of abnormal cellular development and includes solid tumors, non-solid tumors, and any abnormal cellular proliferation, such as that seen in leukemia. As used herein, "cancer" also means angiogenesis-dependent cancers and tumors, 10 *i.e.*, tumors that require for their growth (expansion in volume and/or mass) an increase in the number and density of the blood vessels supplying them with blood. "Regression" refers to the reduction of tumor mass and size. As used herein, the term "therapeutically effective amount" means the total amount of each active component of the composition or method that is sufficient to show a meaningful 15 benefit to a treated human or other mammal, *i.e.*, treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. More specifically, for example, a therapeutically effective amount of an anti-angiogenic chimeric protein can cause a measurable reduction in the size or numbers of tumors, or in their rate of 20 growth or multiplication, compared to untreated tumors. Other methods of assessing a "therapeutically effective amount," can include the result that blood vessel formation is measurably reduced in treated tissues compared to untreated tissues.

One or more anti-angiogenic chimeric proteins may be used in combination with other compositions and procedures for the treatment of diseases. For example, a 25 tumor may be treated conventionally with surgery, radiation, chemotherapy, or immunotherapy, combined with anti-angiogenic chimeric proteins, and then anti-angiogenic chimeric proteins may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize and inhibit the growth of any residual primary tumor.

30 The compositions may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment, such as

chemotherapeutic or radioactive agents. Such additional factors and/or agents may be included in the composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Additionally, administration of the composition of the present invention may be administered concurrently with other
5 therapies, *e.g.*, administered in conjunction with a chemotherapy, immunotherapy or radiation therapy regimen.

The angiogenesis-modulating composition of the present invention may be a solid, liquid or aerosol and may be administered by any known route of administration. Examples of solid compositions include pills, creams, and
10 implantable dosage units. The pills may be administered orally, the therapeutic creams may be administered topically. The implantable dosage unit may be administered locally, for example at a tumor site, or may be implanted for systemic release of the angiogenesis-modulating composition, for example subcutaneously. Examples of liquid composition include formulations adapted for injection
15 subcutaneously, intravenously, intraarterially, and formulations for topical and intraocular administration. Examples of aerosol formulation include inhaler formulation for administration to the lungs.

The anti-angiogenic chimeric proteins can be provided as isolated and substantially purified proteins in pharmaceutically acceptable formulations
20 (including aqueous or nonaqueous carriers or solvents) using formulation methods known to those of ordinary skill in the art. These formulations can be administered by standard routes. In general, the combinations may be administered by the topical, transdermal, intraperitoneal, intracranial, intracerebroventricular, intracerebral, intravaginal, intrauterine, oral, rectal or parenteral (*e.g.*, intravenous, intraspinal,
25 subcutaneous or intramuscular) route. In addition, the anti-angiogenic chimeric proteins may be incorporated into biodegradable polymers allowing for sustained release of the compound, the polymers being implanted in the vicinity of where drug delivery is desired, for example, at the site of a tumor, or implanted so that the anti-angiogenic chimeric proteins is slowly released systemically. Osmotic minipumps
30 may also be used to provide controlled delivery of high concentrations of anti-angiogenic chimeric proteins through cannulae to the site of interest, such as directly

into a growth or into the vascular supply to that growth. The biodegradable polymers and their use are described, for example, in detail in Brem *et al.* (1991) (*J. Neurosurg.* 74:441-446), which is hereby incorporated by reference in its entirety.

As used herein, the terms "pharmaceutically acceptable," as it refers to
5 compositions, carriers, diluents and reagents, represents that the materials are capable of administration to or upon a mammal with a minimum of undesirable physiological effects such as nausea, dizziness, gastric upset and the like. The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art and need not be limited
10 based on formulation. Typically, such compositions are prepared as injectables either as liquid solutions or suspensions, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified, for example, in liposomes.

The dosage of the anti-angiogenic chimeric proteins of the present invention
15 will depend on the disease state or condition being treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. It is to be understood that the present invention has application for both human and veterinary use. The methods of the present invention contemplate single as well as multiple administrations, given either simultaneously
20 or over an extended period of time.

The present invention also encompasses gene therapy whereby a polynucleotide encoding one or more anti-angiogenic chimeric proteins or one or more variants thereof, is introduced and regulated in a patient. Various methods of transferring or delivering DNA to cells for expression of the gene product protein,
25 otherwise referred to as gene therapy, are disclosed in *Gene Transfer into Mammalian Somatic Cells in Vivo*, N. Yang (1992) *Crit. Rev. Biotechnol.* 12(4):335-356, which is hereby incorporated by reference. Gene therapy encompasses incorporation of DNA sequences into somatic cells or germ line cells for use in either ex vivo or in vivo therapy. Gene therapy can function to replace genes,
30 augment normal or abnormal gene function, and to combat infectious diseases and other pathologies.

Strategies for treating these medical problems with gene therapy include therapeutic strategies such as identifying the defective gene and then adding a functional gene to either replace the function of the defective gene or to augment a slightly functional gene; or prophylactic strategies, such as adding a gene for the product protein that will treat the condition or that will make the tissue or organ more susceptible to a treatment regimen. For example, a gene encoding an anti-angiogenic chimeric protein may be inserted into tumor cells of a patient and thus inhibit angiogenesis.

Gene transfer methods for gene therapy fall into three broad categories: physical (e.g., electroporation, direct gene transfer and particle bombardment), chemical (e.g., lipid-based carriers, or other non-viral vectors) and biological (e.g., virus-derived vector and receptor uptake). For example, non-viral vectors may be used which include liposomes coated with DNA. Such liposome/DNA complexes may be directly injected intravenously into the patient. It is believed that the liposome/DNA complexes are concentrated in the liver where they deliver the DNA to macrophages and Kupffer cells. These cells are long lived and thus provide long term expression of the delivered DNA. Additionally, vectors or the "naked" DNA of the gene may be directly injected into the desired organ, tissue or tumor for targeted delivery of the therapeutic DNA.

In vivo gene transfer involves introducing the DNA into the cells of the patient when the cells are within the patient. Methods include using virally mediated gene transfer using a noninfectious virus to deliver the gene in the patient or injecting naked DNA into a site in the patient and the DNA is taken up by a percentage of cells in which the gene product protein is expressed. Additionally, the other methods described herein, such as use of a "gene gun," may be used for *in vitro* insertion of anti-angiogenic chimeric proteins DNA or anti-angiogenic chimeric proteins regulatory sequences.

Chemical methods of gene therapy may involve a lipid based compound, not necessarily a liposome, to transfer the DNA across the cell membrane. Lipofectins or cytofectins, lipid-based positive ions that bind to negatively charged DNA, make a complex that can cross the cell membrane and provide the DNA into the interior of

the cell. Another chemical method uses receptor-based endocytosis, which involves binding a specific ligand to a cell surface receptor and enveloping and transporting it across the cell membrane. The ligand binds to the DNA and the whole complex is transported into the cell. The ligand gene complex is injected into the blood stream
5 and then target cells that have the receptor will specifically bind the ligand and transport the ligand-DNA complex into the cell.

Many gene therapy methodologies employ viral vectors to insert genes into cells. For example, altered retrovirus vectors have been used in *ex vivo* methods to introduce genes into peripheral and tumor-infiltrating lymphocytes, hepatocytes,
10 epidermal cells, myocytes, or other somatic cells. These altered cells are then introduced into the patient to provide the gene product from the inserted DNA.

Viral vectors have also been used to insert genes into cells using *in vivo* protocols. To direct the tissue-specific expression of foreign genes, cis-acting regulatory elements or promoters that are known to be tissue-specific can be used.
15 Alternatively, this can be achieved using *in situ* delivery of DNA or viral vectors to specific anatomical sites *in vivo*. For example, gene transfer to blood vessels *in vivo* was achieved by implanting *in vitro* transduced endothelial cells in chosen sites on arterial walls. The virus infected surrounding cells which also expressed the gene product. A viral vector can be delivered directly to the *in vivo* site, by a catheter for
20 example, thus allowing only certain areas to be infected by the virus, and providing long-term, site specific gene expression. *In vivo* gene transfer using retrovirus vectors has also been demonstrated in mammary tissue and hepatic tissue by injection of the altered virus into blood vessels leading to the organs.

Viral vectors that have been used for gene therapy protocols include but are
25 not limited to, retroviruses, other RNA viruses such as poliovirus or Sindbis virus, adenovirus, adeno-associated virus, herpes viruses, SV40, vaccinia and other DNA viruses. Replication-defective murine retroviral vectors have been widely utilized gene transfer vectors.

Carrier mediated gene transfer *in vivo* can be used to transfect foreign DNA
30 into cells. The carrier-DNA complex can be conveniently introduced into body fluids or the bloodstream and then site-specifically directed to the target organ or

tissue in the body. Both liposomes and polycations, such as polylysine, lipofectins or cytofectins, can be used. Liposomes can be developed which are cell specific or organ specific and thus the foreign DNA carried by the liposome will be taken up by target cells. Injection of immunoliposomes that are targeted to a specific receptor on
5 certain cells can be used as a convenient method of inserting the DNA into the cells bearing the receptor. Another carrier system that has been used is the asialoglycoprotein/polylysine conjugate system for carrying DNA to hepatocytes for *in vivo* gene transfer.

The gene therapy protocol for transfecting anti-angiogenic chimeric proteins
10 into a patient may either be through integration of a gene encoding an anti-angiogenic chimeric protein into the genome of the cells, into minichromosomes or as a separate replicating or non-replicating DNA construct in the cytoplasm or nucleoplasm of the cell. Anti-angiogenic chimeric proteins expression may continue for a long-period of time or may be reinjected periodically to maintain a desired
15 level of the anti-angiogenic chimeric proteins protein in the cell, the tissue or organ or a determined blood level.

EXAMPLES

Example 1: Construction of COMP/TSP-1 and COMP/TSP-2

The chimeric expression vectors have been produced from three distinct
20 cDNAs. The first is a clone for human cartilage oligomeric matrix protein (COMP) and was isolated from a λ gt11 chondrocyte cDNA library (Doege, K.J, *et al.*, *J. Biol. Chem.* 266:894-902 (1991)). This is an almost full-length clone for the COMP mRNA that only lacks a small region of the 5'-untranslated region. This clone (hCOMP-95) was used previously to determine the sequence of human COMP
25 (GenBank Accession No. L32137; *Genomics*, 24:435-439 (1994)).

The second cDNA was produced using the polymerase chain reaction (PCR) with the human thrombospondin-1 (TSP-1) gene as the template. The TSP-1 clones were isolated from a human endothelial cell library (*J. Cell Biol.* 103:1635-1648

(1986)). The forward primer (GAT GAC GTC GAT GGT GGC TGG AGC CAC) (SEQ ID NO: 17) and the reverse primer (GAT CTA GAT TGG ACA GTC CTG CTT G) (SEQ ID NO: 18) produce a PCR product that is approximately 354 basepairs in size and has an Aat II restriction endonuclease site at the 5' end and an Xba I restriction endonuclease site at the 3' end. The PCR product encodes amino acids 417 to 530 and includes the second and third type 1 repeats of TSP-1 (see Figure 1 for the numbering of amino acids in TSP-1). The coding sequence for the first type 1 repeat was not included in the PCR product, by design, because it contains an RFK sequence that has been shown to activate TGF- β . This activity is not required to inhibit angiogenesis and it may produce unwanted secondary effects on numerous cell types. Vectors that include the first type 1 repeat can be constructed, using the same approach, if this region is found to enhance the antiangiogenic activity or other activities.

The third cDNA was produced by PCR with a human heart cDNA library (catalog no. 936208 from Stratagene, LaJolla, CA) as the template. The forward primer (GAT GAC GTC GAG GAG GGC TGG TCT CCG) (SEQ ID NO: 19) and the reverse primer (GAT CTA GAC ACG GGG CAG CTC CTC TTG) (SEQ ID NO: 20) produced a PCR product that is approximately 520 base pairs in size and has an Aat II restriction endonuclease site at the 5' end and an Xba I restriction endonuclease site at the 3' end. The PCR product codes for amino acids 381 to 550 of TSP-2 and, includes all three type 1 repeats of TSP-2 (see Figure 2 for numbering of amino acids in TSP-2). The sequence of the PCR primers was based on the human TSP-2 sequence in the GenBank database (Accession No. L12350). The sequences of the PCR products were determined to establish that mutations that affect the amino acid sequence had not been introduced during the PCR.

The COMP/TSP-1 and COMP-TSP-2 expression vectors were constructed by cutting the PCR products with Aat II and Xba I and subcloning them into the COMP cDNA vector [derived from Bluescript (Stratagene, La Jolla, CA)] cut with the same enzymes. The portion of COMP that was retained includes the signal sequence, the regions required for pentamerization and the first type 2 repeat (amino acids 1 to 128 on the enclosed sequence; Figure 3). Since there was an internal Aat

II site in the TSP-2 PCR product, it had to be cloned into the vector in two steps. A 430 basepair Aat II/Xba I fragment of the TSP-2 PCR product was subcloned into the vector containing the portion of COMP as a first step. The resulting subclone was cut with Aat II, and a 90 base pair Aat II fragment of the PCR product was

5 ligated into the expression vector. The final forms of the cDNAs were confirmed to have the predicted structure by nucleotide sequencing. They were then cut with Eco RI and Xba I and ligated into the pcDNA 3.1 (Invitrogen; Carlsbad, CA) vector cut with the same enzymes. The DNA sequences of COMP/TSP-1 and COMP/TSP-2 are shown in Figures 4A and 4B and Figures 5A and 5B, respectively. The

10 predicted molecular weights of the subunits of COMP/TSP-1 and COMP/TSP-2 should be approximately 24,200 and 30,000, respectively. The fully assembled COMP/TSP-1 and COMP/TSP-2 proteins should be 121,000 Da and 150,000 Da, respectively. The amino acid sequences of these proteins are shown in Figures 4A and 4B and Figures 5A and 5B, respectively.

15 Example 2: Production of Isolated COMP/TSP-1 and COMP/TSP-2

To express these chimeric proteins, the expression vectors can be transfected into human kidney 293 cells using the Lipofectin protocol (Gibco Laboratories). The cells can be selected with Zeocin and individual clones can be grown. The secretion of COMP/TSP-1 and COMP/TSP-2 can be monitored with western

20 blotting using polyclonal antibodies to the region of COMP that is present in both expressed proteins. These antibodies have been produced by immunizing rabbits with a synthetically produced peptide, having an amino acid sequence derived from the N-terminal end of COMP, linked to a carrier protein. The amino acid sequence of the peptide is: SDLGPQMLRELQETN (SEQ ID NO: 21). A clone that

25 expresses high levels of the protein can be grown in large volume flasks and in serum free media.

Example 3: Inhibition of Tumor Growth by COMP/TSP-1

A cDNA of thrombospondin-1 (TSP-1) containing the second and third type-1 repeats and the COMP assembly sequence (COMP/TSP-1) was produced by PCR

using constructs derived as above as template, and was cloned into the expression vector pNeo (Invitrogen, Carlsbad, CA). Both the resulting COMP/TSP-1 construct and the unaltered vector alone were transfected into the human squamous carcinoma cell line A431 (Streit, M., *et al.*, *American Journal of Pathology* 155:441-452, 5 1999), and positive clones were selected using Geneticin at a concentration of 800 $\mu\text{g/ml}$. The growth curves of positive clones were determined over an 8 day period. Clones of pNeo- and COMP/TSP-1 construct-transfected cells that had similar growth curves were selected to test the effect of the chimeric protein on tumor growth in nude mice. A total of five mice per group were injected intradermally at 10 the shoulders with 5×10^6 cells per site, two sites per mouse. Every week the tumors were measured with calipers. At three weeks, the mice were sacrificed and the tumors were removed for further studies. As can be seen from Figure 7, expression of COMP/TSP-1 caused inhibition of the growth of the tumors in this model.

15 All references (e.g., journal articles, books, published patent applications and patents, etc.) cited herein are hereby incorporated by reference.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without 20 departing from the spirit and scope of the invention as defined by the appended claims.

CLAIMS

What is claimed is:

1. A nucleic acid molecule encoding a chimeric protein comprising the second and third type 1 repeats of human TSP-1, but not the TGF- β activation region of human TSP-1.
5
2. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1.
3. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1, but not the TGF- β activation region of human TSP-1.
10
4. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP, the procollagen homology region of TSP-1, and the first, second, and third type 1 repeats of human TSP-1.
15
5. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP, the procollagen homology region of TSP-1, and the first, second, and third type 1 repeats of human TSP-1, but not the TGF- β activation region of human TSP-1.
- 20 6. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP and a portion of human endostatin, wherein the chimeric protein has anti-angiogenic activity.

7. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP and a portion of human angiostatin, wherein the chimeric protein has anti-angiogenic activity.
8. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP and a portion of human prolactin, wherein the chimeric protein has anti-angiogenic activity.
9. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP and a portion of human platelet factor 4, wherein the chimeric protein has anti-angiogenic activity.
- 10 10. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP, the procollagen homology region, and the first, second, and third type 1 repeats of human TSP-1.
11. A nucleic acid molecule encoding a protein having the amino acid sequence SEQ ID NO: 5.
- 15 12. A vector comprising nucleic acid encoding a chimeric protein comprising the second and third type 1 repeats of human TSP-1 but not the TGF- β activation region of human TSP-1.
13. A host cell comprising the vector of Claim 12.
14. A vector comprising nucleic acid encoding a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1.
- 20 15. A host cell comprising the vector of Claim 14.

16. A method for producing a chimeric protein which comprises the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1, said method comprising maintaining the host cell of Claim 15 under conditions suitable for expression of said nucleic acid, whereby said protein is produced.
17. The method of Claim 16 further comprising isolating the chimeric protein.
18. A vector comprising nucleic acid encoding a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1, but not the TGF- β activation region of human TSP-1.
19. A host cell comprising the vector of Claim 18.
20. A method for producing a chimeric protein which comprises the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1, but not the TGF- β activation region of human TSP-1, said method comprising maintaining the host cell of Claim 19 under conditions suitable for expression of said nucleic acid, whereby said protein is produced.
21. The method of Claim 20 further comprising isolating the chimeric protein.
22. A vector comprising nucleic acid encoding a chimeric protein comprising the multimerization domain of human COMP, the procollagen homology region, and the first, second, and third type 1 repeats of human TSP-1.
23. A vector comprising nucleic acid encoding a protein having the amino acid sequence SEQ ID NO: 5.

24. A host cell comprising the vector of Claim 23.
25. A chimeric protein comprising the second and third type 1 repeat of human TSP-1, but not the TGF- β activation region of human TSP-1.
26. A chimeric protein comprising the multimerization domain of human
5 COMP, the first type 2 repeat of human COMP, and the second and third
type 1 repeats of human TSP-1.
27. A chimeric protein comprising the multimerization domain of human
COMP, the first type 2 repeat of human COMP, and the second and third
type 1 repeats of human TSP-1, but not the TGF- β activation region of
10 human TSP-1.
28. A chimeric protein comprising the multimerization domain of human
COMP, the procollagen homology region of TSP-1, and the first, second,
and third type 1 repeats of human TSP-1.
29. A chimeric protein comprising the multimerization domain of human COMP
15 and a portion of human endostatin, wherein the chimeric protein has anti-
angiogenic activity.
30. A chimeric protein comprising the multimerization domain of human COMP
and a portion of human angiostatin, wherein the chimeric protein has anti-
angiogenic activity.
- 20 31. A chimeric protein comprising the multimerization domain of human COMP
and a portion of human prolactin, wherein the chimeric protein has anti-
angiogenic activity.

32. A chimeric protein comprising the multimerization domain of human COMP and a portion of human platelet factor 4, wherein the chimeric protein has anti-angiogenic activity.
33. A protein having the amino acid sequence SEQ ID NO: 5.
- 5 34. An isolated nucleic acid molecule encoding a chimeric protein comprising the three type 1 repeats of human TSP-2.
35. A vector comprising nucleic acid encoding a chimeric protein comprising the three type 1 repeats of human TSP-2.
36. A host cell comprising the vector of Claim 35.
- 10 37. A method for producing a chimeric protein which comprises the three type 1 repeats of human TSP-2, said method comprising maintaining the host cell of Claim 36 under conditions suitable for expression of said nucleic acid, whereby said protein is produced.
38. The method of Claim 37 further comprising isolating the chimeric protein.
- 15 39. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the three type 1 repeats of human TSP-2.
40. A vector comprising isolated nucleic acid encoding a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the three type 1 repeats of human TSP-2.
- 20 41. A host cell comprising the vector of Claim 40.

42. A method for producing a chimeric protein which comprises the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the three type 1 repeats of human TSP-2, said method comprising maintaining the host cell of Claim 41 under conditions suitable for expression of said nucleic acid, whereby said protein is produced.
43. The method of Claim 42 further comprising isolating the chimeric protein.
44. A nucleic acid molecule encoding a protein having the amino acid sequence SEQ ID NO: 7.
45. A vector comprising nucleic acid encoding a protein having the amino acid sequence SEQ ID NO: 7.
46. A host cell comprising the vector of Claim 45.
47. A chimeric protein comprising the three type 1 repeats of human TSP-2.
48. A chimeric protein comprising the procollagen homology region of TSP-2 and the three type 1 repeats of human TSP-2.
49. A chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the three type 1 repeats of human TSP-2.
50. A protein having the amino acid sequence SEQ ID NO: 7.
51. A method for inhibiting angiogenesis in a human or other mammal, the method comprising administering to the human or other mammal a therapeutically effective amount of an anti-angiogenic chimeric protein.

52. The method of Claim 51 wherein the anti-angiogenic chimeric protein is selected from the group consisting of:
- a) a chimeric protein comprising the second and third type 1 repeats of human TSP-1;
 - 5 b) a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1;
 - c) a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and
10 third type 1 repeats of human TSP-1, but not the TGF- β activation region of human TSP-1;
 - d) a chimeric protein comprising the multimerization domain of human COMP, the procollagen region, and the first, second, and third type 1 repeats of human TSP-1; and
 - 15 e) a chimeric protein comprising the three type 1 repeats of human TSP-2; and (6) a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the three type 1 repeats of human TSP-2.
53. The method of Claim 51 wherein the anti-angiogenic protein is administered
20 locally at the site of one or more growths.

1/9

human thrombospondin-1

1 NRIPESGGDNSVFDIFELTGAARKSGRRLLVKGPDSPSPAFRIEDANLIPVPDDKFDL
 61 VDAVRTEKGFLLASLRQHKKTRGTLALERKDHSGQVFSVSNKAGTLDLSLTVQGKQ
 121 HVVSEEAALLATGQWKSITLFVQEDRAQLYIDCEKHNABLDVPIQSVFTRDLASIALRL
 181 IAKGGVNDNFQGVLQNVRFVGTTPEDILRNKGCSSSTSVLLTLDNVNV[®]GGSSPAIRTNV
 241 IGHKTKDLQAICGISCDELSSM
 263 VLELRGLRTIVTTLQDSIRKVTENKELANELRRPPLCYHNGVQYRNNE
 312 EWTVDSCTECHCQNSVTICKKVCPI[®]MPCSNATVPDGECCPRCWPSDSA
 361 DDGWSPWSEWTSCTSCGNGIQQRGRSCDSLNR-----CEGSSVQTRTCHIQECDKRFKQ
 417 DGGWSHSPWS/CSVTCTEDGVITRILCN[®]SPSPQMNKPKCEGEARETKACKKDACPI
 474 NGWGPWSPWDICSVTCGGGVQKRSHLCN[®]PTPQFGGKDCVDVTENQICNKKQDCPI
 531 DGCLSNP--CFAGV--KCT--SYDGSWKCGACPPGYSG-----NGIQCTDV
 572 DECKEVPDACFNHNGEHRCE-----TDPGYNCLPCPPRFTGSQPPGQGVHATANKQVCKPR
 630 NPCTDGTDCNKNA---KCHYLGHYSDPMYRC-ECKPGYAG-----NGIICGE
 674 DTDLDGWPNE[®]NLVCVANATYHCKK
 698 DNCNLPNSGQEDYDKDIGDACDD--DDDN[®]KIPDDR
 734 DNCPPHYNPAQYDYDRDDVGDR
 757 D[®]NC[®]PNHNPDQADTDNNGEGDACA--DIDG[®]GILNER
 793 D[®]NCQYVYNVDQRTDM[®]DGVGDQ
 816 D[®]NCPLHNPDQLSDSDRIGDTC[®]DN[®]QDI[®]DE[®]GHQNNL
 854 D[®]NC[®]PYV[®]PNANQADHK[®]DGK[®]GDA[®]CDH--DD[®]ND[®]GIPDDK
 890 D[®]NCRLV[®]PNPDQK[®]SDG[®]DGRGDA[®]CKD--DFD[®]H[®]SV[®]PDID
 926 DICPENVDISETDPRRFQMIPLDPKGTSDNDPNWVRHQKELVQVNCOPGLAVGYDEF
 986 NAVDFSGTFFIN[®]TERDDYAGFVFGYQSSSRFYVVMKQVTSYNDT[®]PT[®]RAQGYSGLSV
 1046 KVV[®]STTGPGEHLRNALWHTGNTPGQV[®]RTLWHDPRHIGK[®]DF[®]TAYR[®]RLSHR[®]PKT[®]GF[®]IRV
 1106 VMYRGKKIMADSGPIYDKTYAGGRGLGVFSQEMVFFSDLYE[®]CRDP

Fig. 1

2/9

human thrombospondin-2

NH₂
 1 NVWRLLVLLALHVMFSTQAGHQDKDTTFDLFSISINRKTIGAKQFRGPDGVPAYRPFVRF
 61 DYIPPVNADDLTKITKIMRQKEGFFELTAQLKQDGESESGTLALLEGPGLSQRQFEIVSNGP
 121 ADTLDLTYWIDGTRHVVSLVDGLADSQW¹²¹TVQVAGETYSLVHVGCDLIGPVALDEPFY
 181 EHLQAEKSRMYVAKGSARSHFRGLLQNVHLVFNHVEDILSKKGCQCGQGAENAISEN
 241 TETRLGPHVTTEYVGPSSRRRPEVCERSCEELGHN
 P
 277 VQELSGLHVLVNLSENLRKRVSNQFLWELIGGPPKTR²⁷⁷MSACWQDGRFFA²⁷⁷DE
 332 TWVVDSCCTCTCKKFKTICHQITCPPATCASPSFVEGECCEPCLHSVDG
 type 1
 381 EEGWSPWAEWTQCSVT³⁸¹CGSGTQQRGRSCDVSTNT-----CLGPSIQTRACSLSKCDTRIRQ
 437 DGGWHSWSPWSSCSVT⁴³⁷CGV⁴³⁷ITRIRLCNSPVPMGKNCCKSGRETAKCQGAPCPI
 494 DGRWSPWSPWASACTVTCAGGIRERTRVCNSPEPQYGGKACVGDVQERQKCNKRSCP
 type 2
 551 DGCLSNP---CFPGA---QCS---SFPDGSWSCGFCPVGFLG-----⁵⁵¹NGTHCEDL
 592 DECALVPDIDCFSTSKVPRCVN---TQGFPHCLPCPPRYRGNQPVGVGLEAAKTEKQVCEPE
 650 NPCKDKTHNCHKHA---ECIYLGHFSDPMYKCE-CQTGYAG-----DGLICGE
 694 DSDLDGWPNLNLVLCAT⁶⁹⁴ATYHCIK
 type 3
 718 DNCPLPNSGQEDFDKDGIGDACDD---DDDNDGVTDK
 748 DNCQLLFNPRQADYDKDEVGDR
 777 DNCPLYHNPAQIDTNNNGEGDACS---DIDGDDVFNER
 813 DNCPLYVNTDQDRTDGDGVGDHC
 836 DNCPLVHNPQTDVNDLVGDQCDNNEIDDDGHEQNNQ
 874 DNCPLYSNANQADHRRDGGDACDP---DDDNDGVPPDR
 910 DNCRLVFNPDQEDLDGDGRG⁹¹⁰DICKD---DPDNDNI⁹¹⁰PDID
 COOH
 946 DVCPENNAISETDFRNFQMVPLDPKGTQIDPNWVIRHQKELVQTANSPPGIAVGDFEF
 1006 GSVDFSGTFYVNTDRDDDYAGFVGYQSSSRFYVMKQVTTQTYWEDQPTRAYGYSVSL
 1066 KVV¹⁰⁶⁶STGTGTEHLRNALNHTGNTPGQVRTLWHD¹⁰⁶⁶PRNIGWKDITYARWHLTHRPKTYIRV
 1126 LVHEGKQVMADSGPIYDQTYAGGRGLGFVPSQEMVYPSDLKYECDI

FIG. 2

human COMP

1 M V P D T A C V L L L T L A A L G A S G Q G S P L G S D L G P Q M L R E L Q E T N A A L Q D V R D W L R Q Q V R E I T
61 F L K N T V M E C D A C G M Q Q S V R T G L P S V R P L
89 L H C A P G F - - - C F P G V A C I Q T E S G G R - C G P C P A G P T G - - - - - (N) G S H C T D V
129 N E C N A H P - - - C F P R V R C I (N) T S P G F R - C E A C P P G Y S G P T H Q G V G L A F A K A N K Q V C T D I
type 2 182 N E C E T G Q H N - C V P N S V C I N T R G S F Q - C G P C Q P G F V G - - - - - D Q A S G C Q R G A Q
227 R F C P D G S P S E C H E H A D C V L E R D G S R S C V - C R V G W A G - - - - - N G I L C G R
269 D T D L D G F P D E K L R C P E P Q C R K
290 D N C V T V P N S G Q E D V D R D G I G D A C D - - P D A D G D G V P N E K
326 D N C P L V R N P D Q R N T D E D K W G D A C
349 D N C R S Q K N D D Q K D T D Q D G R G D A C D - - D D I D G D R I R N Q A
type 3 385 D N C P R V P N S D Q K D S D G D G I G D A C
408 D N C P Q K S N P D Q A D V D H D F V G D A C D S D Q D Q D G D G H Q D S R
446 D N C P T V P N S A Q E D S D H D G Q G D A C D - - D D D D N D G V P D S R
482 D N C R L V P N P G Q E D A D R D G V G D V C Q - - D D F D A D K V V D K I
518 D V C P E N A E V T L T D P R A F Q T V V L D P E G D A Q I D P N W V V L N Q G R E I V Q T M N S D P G L A V G Y T A F
COOH 578 N G V D F E G T F H V N T V T D D D Y A G F I F G Y Q D S S F Y V V M W K Q M E Q T Y W Q A N P F R A V A E P G I Q L
638 K A V K S S T G P G E Q L R N A L W H T G D T E S Q V R L L W K D P R N V G W K D K S Y R W F L Q H R P Q V G Y I R V
698 R F Y E G P E L V A D S N V V L D T T M R G G R L G V F C F S Q E N I I W A N L R Y R C (N) D T I P E D Y E T H Q L R Q A

Fig. 3

CAGCACCCAG CTCCCCGCCA CCGCC ATG GTC CCC GAC ACC GCC TGC GTT CTT	52
Met Val Pro Asp Thr Ala Cys Val Leu	
1 5	
CTG CTC ACC CTG GCT GCC CTC GGC GCG TCC GGA CAG GGC CAG AGC CCG	100
Leu Leu Thr Leu Ala Ala Leu Gly Ala Ser Gly Gln Gly Gln Ser Pro	
10 15 20 25	
TTG GGC TCA GAC CTG GGC CCG CAG ATG CTT CGG GAA CTG CAG GAA ACC	148
Leu Gly Ser Asp Leu Gly Pro Gln Met Leu Arg Glu Leu Gln Glu Thr	
30 35 40	
AAC GCG GCG CTG CAG GAC GTG CCG GAC TGG CTG CGG CAG CAG GTC AGG	196
Asn Ala Ala Leu Gln Asp Val Arg Asp Trp Leu Arg Gln Gln Val Arg	
45 50 55	
GAG ATC ACG TTC CTG AAA AAC ACG GTG ATG GAG TGT GAC GCG TGC GGG	244
Glu Ile Thr Phe Leu Lys Asn Thr Val Met Glu Cys Asp Ala Cys Gly	
60 65 70	
ATG CAG CAG TCA GTA CGC ACC GGC CTA CCC AGC GTG CGG CCC CTG CTC	292
Met Gln Gln Ser Val Arg Thr Gly Leu Pro Ser Val Arg Pro Leu Leu	
75 80 85	
CAC TGC GCG CCC GGC TTC TGC TTC CCC GGC GTG GCC TGC ATC CAG ACG	340
His Cys Ala Pro Gly Phe Cys Phe Pro Gly Val Ala Cys Ile Gln Thr	
90 95 100 105	
GAG AGC GGC GGC CGC TGC GGC CCC TGC CCC GCG GGC TTC ACG GGC AAC	388
Glu Ser Gly Gly Arg Cys Gly Pro Cys Pro Ala Gly Phe Thr Gly Asn	
110 115 120	

FIG 4A

5/9

GGC TCG CAC TGC ACC GAC GTC GAT GGT GGC TGG AGC CAC TGG TCC CCG	436
Gly Ser His Cys Thr Asp Val Asp Gly Gly Trp Ser His Trp Ser Pro	
125 130 135	
TGG TCA TCT TGT TCT GTG ACA TGT GGT GAT GGT GTG ATC ACA AGG ATC	484
Trp Ser Ser Cys Ser Val Thr Cys Gly Asp Gly Val Ile Thr Arg Ile	
140 145 150	
CGG CTC TGC AAC TCT CCC AGC CCC CAG ATG AAC GGG AAA CCC TGT GAA	532
Arg Leu Cys Asn Ser Pro Ser Pro Gln Met Asn Gly Lys Pro Cys Glu	
155 160 165	
GGC GAA GCG CGG GAG ACC AAA GCC TGC AAG AAA GAC GCC TGC CCC ATC	580
Gly Glu Ala Arg Glu Thr Lys Ala Cys Lys Lys Asp Ala Cys Pro Ile	
170 175 180 185	
AAT GGA GGC TGG GGT CCT TGG TCA CCA TGG GAC ATC TGT TCT GTC ACC	628
Asn Gly Gly Trp Gly Pro Trp Ser Pro Trp Asp Ile Cys Ser Val Thr	
190 195 200	
TGT GGA GGA GGG GTA CAG AAA CGT AGT CGT CTC TGC AAC AAC CCC ACA	676
Cys Gly Gly Gly Val Gln Lys Arg Ser Arg Leu Cys Asn Asn Pro Thr	
205 210 215	
CCC CAG TTT GGA GGC AAG GAC TGC GTT GGT GAT GTA ACA GAA AAC CAG	724
Pro Gln Phe Gly Gly Lys Asp Cys Val Gly Asp Val Thr Glu Asn Gln	
220 225 230	
ATC TGC AAC AAG CAG GAC TGT CCA ATC TAG A	755
Ile Cys Asn Lys Gln Asp Cys Pro Ile *	
235 240	

FIG. 4B


CAGCACCCAG	CTCCCCGCCA	CCGCC	ATG	GTC	CCC	GAC	ACC	GCC	TGC	GTT	CTT						52
			Met	Val	Pro	Asp	Thr	Ala	Cys	Val	Leu						
			1				5										
CTG	CTC	ACC	CTG	GCT	GCC	CTC	GGC	GCG	TCC	GGA	CAG	GGC	CAG	AGC	CCG		100
Leu	Leu	Thr	Leu	Ala	Ala	Leu	Gly	Ala	Ser	Gly	Gln	Gly	Gln	Ser	Pro		
10				15					20						25		
TTG	GGC	TCA	GAC	CTG	GGC	CCG	CAG	ATG	CTT	CGG	GAA	CTG	CAG	GAA	ACC		148
Leu	Gly	Ser	Asp	Leu	Gly	Pro	Gln	Met	Leu	Arg	Glu	Leu	Gln	Glu	Thr		
				30					35					40			
AAC	GCG	GCG	CTG	CAG	GAC	GTG	CGG	GAC	TGG	CTG	CGG	CAG	CAG	GTC	AGG		196
Asn	Ala	Ala	Leu	Gln	Asp	Val	Arg	Asp	Trp	Leu	Arg	Gln	Gln	Val	Arg		
			45					50					55				
GAG	ATC	ACG	TTC	CTG	AAA	AAC	ACG	GTG	ATG	GAG	TGT	GAC	GCG	TGC	GGG		244
Glu	Ile	Thr	Phe	Leu	Lys	Asn	Thr	Val	Met	Glu	Cys	Asp	Ala	Cys	Gly		
		60					65					70					
ATG	CAG	CAG	TCA	GTA	CGC	ACC	GGC	CTA	CCC	AGC	GTG	CGG	CCC	CTG	CTC		292
Met	Gln	Gln	Ser	Val	Arg	Thr	Gly	Leu	Pro	Ser	Val	Arg	Pro	Leu	Leu		
	75					80					85						
CAC	TGC	GCG	CCC	GGC	TTC	TGC	TTC	CCC	GGC	GTG	GCC	TGC	ATC	CAG	ACG		340
His	Cys	Ala	Pro	Gly	Phe	Cys	Phe	Pro	Gly	Val	Ala	Cys	Ile	Gln	Thr		
90				95					100						105		
GAG	AGC	GGC	GGC	CGC	TGC	GGC	CCC	TGC	CCC	GCG	GGC	TTC	ACG	GGC	AAC		388
Glu	Ser	Gly	Gly	Arg	Cys	Gly	Pro	Cys	Pro	Ala	Gly	Phe	Thr	Gly	Asn		
				110				115						120			
GGC	TCG	CAC	TGC	ACC	GAC	GTC	GAG	GAG	GGC	TGG	TCT	CCG	TGG	GCA	GAG		436
Gly	Ser	His	Cys	Thr	Asp	Val	Glu	Glu	Gly	Trp	Ser	Pro	Trp	Ala	Glu		
			125				130						135				
TGG	ACC	CAG	TGC	TCC	GTG	ACG	TGT	GGC	TCT	GGG	ACC	CAG	CAG	AGA	GGC		484
Trp	Thr	Gln	Cys	Ser	Val	Thr	Cys	Gly	Ser	Gly	Thr	Gln	Gln	Arg	Gly		
		140					145					150					

FIG. 5A


CGG TCC TGT GAC GTC ACC AGC AAC ACC TGC TTG GGG CCC TCG ATC CAG	532
Arg Ser Cys Asp Val Thr Ser Asn Thr Cys Leu Gly Pro Ser Ile Gln	
155 160 165	
ACA CGG GCT TGC AGT CTG AGC AAG TGT GAC ACC CGC ATC CGG CAG GAC	580
Thr Arg Ala Cys Ser Leu Ser Lys Cys Asp Thr Arg Ile Arg Gln Asp	
170 175 180 185	
GGC GGC TGG AGC CAC TGG TCA CCT TGG TCT TCA TGC TCT GTG ACC TGT	628
Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser Val Thr Cys	
190 195 200	
GGA GTT GGC AAT ATC ACA CGC ATC CGT CTC TGC AAC TCC CCA GTG CCC	676
Gly Val Gly Asn Ile Thr Arg Ile Arg Leu Cys Asn Ser Pro Val Pro	
205 210 215	
CAG ATG GGG GGC AAG AAT TGC AAA GGG AGT GGC CGG GAG ACC AAA GCC	724
Gln Met Gly Gly Lys Asn Cys Lys Gly Ser Gly Arg Glu Thr Lys Ala	
220 225 230	
TGC CAG GGC GCC CCA TGC CCA ATC GAT GGC CGC TGG AGC CCC TGG TCC	772
Cys Gln Gly Ala Pro Cys Pro Ile Asp Gly Arg Trp Ser Pro Trp Ser	
235 240 245	
CCG TGG TCG GCC TGC ACT GTC ACC TGT GCC GGT GGG ATC CGG GAG CGC	820
Pro Trp Ser Ala Cys Thr Val Thr Cys Ala Gly Gly Ile Arg Glu Arg	
250 255 260 265	
ACC CGG GTC TGC AAC AGC CCT GAG CCT CAG TAC GGA GGG AAG GCC TGC	868
Thr Arg Val Cys Asn Ser Pro Glu Pro Gln Tyr Gly Gly Lys Ala Cys	
270 275 280	
GTG GGG GAT GTG CAG GAG CGT CAG ATG TGC AAC AAG AGG AGC TGC CCC	916
Val Gly Asp Val Gln Glu Arg Gln Met Cys Asn Lys Arg Ser Cys Pro	
285 290 295	
GTG TCT AGA	925
Val Ser Arg	

FIG. 5B


COMP/TSP-1




COMP/ENDOSTATIN



COMP/TSP-1P



COMP/TSP-2



pentamerization domain of human COMP



type 2 repeat of human COMP



second and third type 1 repeats of TSP-1



all three type1 repeats of TSP-1 or -2



procollagen homology region



endostatin




FIG. 7

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 August 2000 (03.08.2000)

PCT

(10) International Publication Number
WO 00/44908 A3

- (51) International Patent Classification⁷: **C12N 15/52**,
C07K 14/78, 19/00, A61K 38/17
- (21) International Application Number: PCT/US00/02482
- (22) International Filing Date: 1 February 2000 (01.02.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/118,053 1 February 1999 (01.02.1999) US
- (71) Applicant (*for all designated States except US*): **BETH ISRAEL DEACONESS MEDICAL CENTER** [US/US];
330 Brookline Avenue, Boston, MA 02215 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **LAWLER, John, W.**
[US/US]; 6 Gale Road, Swampscott, MA 01907 (US).
- (74) Agents: **HOGLE, Doreen, M. et al.**; Hamilton, Brook,
Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA
02421 (US).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— *With international search report.*
- (88) Date of publication of the international search report:
15 February 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 00/44908 A3

(54) Title: COMP/TSP-1, COMP/TSP-2 AND OTHER TSP CHIMERIC PROTEINS

(57) Abstract: Tumors attract blood vessels in order to grow by a process called angiogenesis. The relative quantity of stimulators and inhibitors is an important determining factor for the initiation of angiogenesis. Thrombospondins-1 and -2 are adhesive glycoproteins that have the ability to inhibit angiogenesis. This inhibiting activity has been mapped to the type 1 repeats of TSP-1 and TSP-2. The invention includes chimeric proteins that contain anti-angiogenic portions of TSP-1, TSP-2, endostatin, angiostatin, platelet factor 4, or prolactin, linked to a portion of the N-terminal region of human cartilage oligomeric matrix protein (COMP) that allows formation of pentamers. Also described herein are the nucleic acid molecules, vectors, and host cells for expressing and producing these chimeric proteins. Further embodiments of the invention include methods to treat humans or other mammals with anti-angiogenic proteins to reduce tumor size or rate of growth. Since the type 1 repeat region of TSP-1 and TSP-2 reportedly inhibits HIV infection, chimeric proteins comprising these repeats may also be used for this purpose, as well as to inhibit angiogenesis.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/02482

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/52 C07K14/78 C07K19/00 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, CHEM ABS Data, BIOSIS, MEDLINE, SCISEARCH, BIOTECHNOLOGY ABS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PANETTI TS ET AL: "Interaction of recombinant procollagen and properdin modules of thrombospondin-1 with heparin and fibrinogen/fibrin." JOURNAL OF BIOLOGICAL CHEMISTRY, JAN 1 1999, 274 (1) P430-7, XP002140107	1,12,13, 25
A	UNITED STATES abstract; figure 2B	2-5,10, 11, 14-24, 26-28

	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

21 September 2000

Date of mailing of the international search report

18. 10. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	QABAR AZIZ N ET AL: "A chimeric murine TSP3/human TSP1 is a pentamer with abolished antiangiogenic activity." ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY 97;NEW ORLEANS, LOUISIANA, USA; APRIL 6-9, 1997, vol. 11, no. 3, 1997, page A63 XP000914726 FASEB Journal 1997 ISSN: 0892-6638 the whole document ---	1,12,13, 25
A	WO 98 18943 A (CIBA GEIGY AG ;KAJAVA ANDREY (CH); UNIV LAUSANNE (CH); CRAMERI RET) 7 May 1998 (1998-05-07) abstract; claims 1-32 ---	1-5, 10-28,33
A	WO 98 39418 A (ARIAD GENE THERAPEUTICS INC ;GILMAN MICHAEL Z (US)) 11 September 1998 (1998-09-11) claims 1-5 ---	1-5, 10-28,33
A	WO 93 16716 A (UNIV NORTHWESTERN) 2 September 1993 (1993-09-02) claims 1-11; figures SEQ.ID.1,2 ---	1-5, 10-28,33
A	KUNO ET AL: "Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene" JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 1, 3 January 1997 (1997-01-03), pages 556-562, XP002076038 ISSN: 0021-9258 abstract; figures 5,6 ---	1-5, 10-28,33
Y	WO 96 37621 A (HOESS ADOLF ;PACK PETER (DE); MORPHOSYS PROTEINOPTIMIERUNG (DE)) 28 November 1996 (1996-11-28) claims 1,4-7 ---	6-9, 29-32
Y	EP 0 407 122 A (REPLIGEN CORP) 9 January 1991 (1991-01-09) claims 1-23 ---	9,32
Y	WO 98 54217 A (CHILDRENS MEDICAL CENTER) 3 December 1998 (1998-12-03) abstract; claims 1-15 ---	7,30
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 51323 A (STRUMAN INGRID ;MARTIAL JOSEPH A (BE); TAYLOR ROBERT (US); UNIV CA) 19 November 1998 (1998-11-19) abstract; claims 1-26 ---	8,31
Y	NGUYEN JOSEPHINE T ET AL: "Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy." CANCER RESEARCH, vol. 58, no. 24, 15 December 1998 (1998-12-15), pages 5673-5677, XP000857408 ISSN: 0008-5472 the whole document ---	6,29
A	TOMSCHY ANDREA ET AL: "Homophilic adhesion of E-cadherin occurs by a co-operative two-step interaction of N-terminal domains." EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 15, no. 14, 1996, pages 3507-3514, XP002147181 ISSN: 0261-4189 the whole document ---	6-9, 29-32
A	TERSKIKH ALEXEY V ET AL: "'Peptabody": A new type of high avidity binding protein." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 5, 1997, pages 1663-1668, XP002147182 1997 ISSN: 0027-8424 the whole document ---	6-9, 29-32
A	NEWTON GAIL ET AL: "Characterization of human and mouse cartilage oligomeric matrix protein." GENOMICS, vol. 24, no. 3, 1994, pages 435-439, XP002147953 ISSN: 0888-7543 the whole document ---	34-50
A	O'ROURKE KM ET AL: "Thrombospondin 1 and thrombospondin 2 are expressed as both homo- and heterotrimers." JOURNAL OF BIOLOGICAL CHEMISTRY, DEC 15 1992, 267 (35) P24921-4, XP002147183 UNITED STATES the whole document -----	34-50

INTERNATIONAL SEARCH REPORT

International application No
PCT/US 00/02482

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 51-53 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 51-53 partially and 1-5,10-28 ,33

TSP-1 chimeric protein constructs, corresponding nucleic acids ,vectors ,host cells , method of producing chimeric proteins

2. Claims: 51-53 partially and 34-50

TSP-2 chimeric protein constructs, corresponding nucleic acids ,vectors ,host cells ,method of producing chimeric proteins

3. Claims: 51-53 partially and 6-9, 29-32

COMP chimeric protein constructs, not provided in the first and second invention of present application , corresponding nucleic acids ,vectors ,host cells , method of producing chimeric proteins

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/02482

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9818943 A	07-05-1998	AU 6909298 A EP 0938571 A	22-05-1998 01-09-1999
WO 9839418 A	11-09-1998	AU 6692298 A	22-09-1998
WO 9316716 A	02-09-1993	NONE	
WO 9637621 A	28-11-1996	CA 2222055 A EP 0827544 A JP 11508126 T	28-11-1996 11-03-1998 21-07-1999
EP 0407122 A	09-01-1991	US 5112946 A AT 143698 T CA 2019086 A DE 69028739 D DE 69028739 T DK 407122 T EP 0723015 A ES 2092493 T GR 3021658 T JP 3063297 A	12-05-1992 15-10-1996 06-01-1991 07-11-1996 13-02-1997 17-02-1997 24-07-1996 01-12-1996 28-02-1997 19-03-1991
WO 9854217 A	03-12-1998	US 5945403 A AU 7704998 A EP 0996632 A	31-08-1999 30-12-1998 03-05-2000
WO 9851323 A	19-11-1998	AU 7383298 A	08-12-1998

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 August 2000 (03.08.2000)

PCT

(10) International Publication Number
WO 00/44908 A3

(51) International Patent Classification: **C12N 15/52**,
C07K 14/78, 19/00, A61K 38/17

DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US00/02482

(22) International Filing Date: 1 February 2000 (01.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
60/118,053 1 February 1999 (01.02.1999) US

Published:
-- with international search report

(71) Applicant (*for all designated States except US*): **BETH
ISRAEL DEACONESS MEDICAL CENTER** [US/US];
330 Brookline Avenue, Boston, MA 02215 (US).

(88) Date of publication of the international search report:
15 February 2001

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **LAWLER, John, W.**
[US/US]; 6 Gale Road, Swampscott, MA 01907 (US).

(48) Date of publication of this corrected version:
14 February 2002

(74) Agents: **HOGLE, Doreen, M.** et al.; Hamilton, Brook,
Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA
02421 (US).

(15) Information about Correction:
see PCT Gazette No. 07/2002 of 14 February 2002, Section
II

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMP/TSP-1, COMP/TSP-2 AND OTHER TSP CHIMERIC PROTEINS

(57) Abstract: Tumors attract blood vessels in order to grow by a process called angiogenesis. The relative quantity of stimulators and inhibitors is an important determining factor for the initiation of angiogenesis. Thrombospondins-1 and -2 are adhesive glycoproteins that have the ability to inhibit angiogenesis. This inhibiting activity has been mapped to the type 1 repeats of TSP-1 and TSP-2. The invention includes chimeric proteins that contain anti-angiogenic portions of TSP-1, TSP-2, endostatin, angiostatin, platelet factor 4, or prolactin, linked to a portion of the N-terminal region of human cartilage oligomeric matrix protein (COMP) that allows formation of pentamers. Also described herein are the nucleic acid molecules, vectors, and host cells for expressing and producing these chimeric proteins. Further embodiments of the invention include methods to treat humans or other mammals with anti-angiogenic proteins to reduce tumor size or rate of growth. Since the type 1 repeat region of TSP-1 and TSP-2 reportedly inhibits HIV infection, chimeric proteins comprising these repeats may also be used for this purpose, as well as to inhibit angiogenesis.

WO 00/44908 A3

-1-

COMP/TSP-1, COMP/TSP-2 AND OTHER CHIMERIC PROTEINS

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/118,053 filed February 1, 1999, the entire teachings of which are incorporated
5 herein by reference.

BACKGROUND OF THE INVENTION

Thrombospondins are a family of calcium-binding multifunctional glycoproteins that are secreted by various cell types and are developmentally regulated components of the extracellular matrix (Bornstein, P., *FASEB J.*, 6:3290-
10 3299, 1992; Bornstein, P., *J. Cell Biol.*, 130:503-506, 1995). Among their functions are modulating cell attachment, migration and proliferation.

One member of this family, cartilage oligomeric matrix protein (COMP) is a pentamer in which multimerization appears to be directed by α -helical segments situated (in the amino acid sequence) either before or after the cysteine residues that
15 form the interchain disulfide bonds. COMP has been purified (Prochownik, E.V. *et al.*, *J. Cell Biol.* 109:843-852 (1989)). Individuals affected with pseudoachondroplasia, who have considerably shortened stature as a result of premature cessation of bone growth, have been shown to have mutations in exon 17B of the COMP protein (*Nature Genetics* 10:325-329 (1995)).

20 In vitro assays have shown that platelet thrombospondin-1 is involved in thrombosis, fibrinolysis, wound healing, inflammation, tumor cell metastasis and angiogenesis. The major form of thrombospondin secreted by platelets and endothelial cells is TSP-1. Thrombospondin-1 (TSP-1) is an angiogenesis inhibitor that decreases tumor growth. Thrombospondin- 2 (TSP-2) is a related glycoprotein
25 of similar structure and properties.

The thrombospondin type 1 repeats (TSRs; also "repeat regions" herein) have been shown to inhibit angiogenesis and HIV infection. However, other portions of the proteins have been shown to have a positive effect on endothelial cell

-2-

growth. Thrombospondin-1 and -2 are similar in terms of their molecular architecture. Thrombospondin-1 and thrombospondin-2 each have three copies of the TSR. TSP-1 and TSP-2 are trimeric molecules. Thus, each fully assembled protein contains nine TSRs.

5 Whereas TSP-1 and TSP-2 are antiangiogenic, these proteins contain other domains that have additional activities that diminish the antiangiogenic activity. The isolated TSRs are more potent inhibitors of angiogenesis than the native molecules.

 The ingrowth of new capillary networks into developing tumors is essential
10 for the progression of cancer. Thus, the development of pharmaceuticals that inhibit the process of angiogenesis is an important therapeutic goal. As pointed out in a review by Folkman (Folkman, J., *Proc. Natl. Acad. Sci. USA* 95: 9064-9066, 1998), antiangiogenic therapy has little toxicity, does not require the therapeutic agent to enter tumor cells or cross the blood-brain barrier, controls tumor growth
15 independently of growth of tumor cell heterogeneity, and does not induce drug resistance.

SUMMARY OF THE INVENTION

 The invention includes chimeric proteins comprising: (1) a chimeric protein comprising the second and third type 1 repeats of human TSP-1, and which may also
20 comprise the procollagen homology region of TSP-1; (2) a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1; (3) a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human
25 TSP-1, but not the TGF- β activation region of human TSP-1; (4) a chimeric protein comprising the multimerization domain of human COMP, the procollagen region, and the first, second, and third type 1 repeats of human TSP-1; (5) a chimeric protein comprising the three type 1 repeats of human TSP-2, and which may also comprise the procollagen homology region of TSP-2; (6) a chimeric protein comprising the
30 multimerization domain of human COMP, the first type 2 repeat of human COMP,

and the three type 1 repeats of human TSP-2; and (7) variants of any of the above having anti-angiogenic activity. The invention further includes isolated nucleic acids encoding any of the above chimeric proteins, vectors comprising these nucleic acids, and host cells comprising any of said vectors. The chimeric proteins can be
5 produced in host cells and used in methods for the treatment of a disease or medical condition characterized by abnormal or undesirable proliferation of blood vessels, such as that occurring in tumor growth.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a representation of the amino acid sequence of human TSP-1
10 (SEQ ID NO: 1). The type 1 repeats of TSP-1 are, as illustrated here, 1) amino acids 361-416; 2) amino acids 417-473; and 3) amino acids 474-530.

Figure 2 is a representation of the amino acid sequence of human TSP-2 (SEQ ID NO: 2). The type 1 repeats of TSP-2 are, as illustrated here, 1) amino acids 381-436; 2) amino acids 437-493; and 3) amino acids 494-550.

15 Figure 3 is a representation of the amino acid sequence of human COMP (SEQ ID NO: 3). The type 2 repeats of COMP are, as illustrated here, 1) amino acids 89-128; 2) amino acids 129-181; 3) amino acids 182-226; and 4) amino acids 227-268

Figures 4A and 4B together are a representation of the DNA sequence (SEQ
20 ID NO: 4) of gene encoding a human COMP/TSP-1 chimeric protein and the amino acid sequence (SEQ ID NO: 5) of a human COMP/TSP-1 chimeric protein encoded by the DNA sequence above it.

Figure 5A and 5B together are a representation of the DNA sequence (SEQ
ID NO: 6) of a gene encoding a human COMP/TSP-2 chimeric protein and the
25 amino acid sequence (SEQ ID NO: 7) of a human COMP/TSP-2 chimeric protein encoded by the DNA sequence above it.

Figure 6 is a schematic representation of a few of the chimeric protein embodiments of the invention.

Figure 7 is a graph showing tumor volume (mm^3) at 7, 14 and 21 days in the
30 experiment described in Example 3, in which mice were injected with an unaltered

(control) vector, pNeo (filled diamonds) or with an expression vector encoding COMP/TSP-1 chimeric protein (filled squares).

DETAILED DESCRIPTION OF THE INVENTION

Described herein is a protein that has the functional activity of the TSR but
5 not other activities associated with TSP-1 or TSP-2, and is assembled into a
multimeric structure. One embodiment of the invention is a chimeric protein that
comprises the TSRs from TSP-1 or TSP-2 and the multimer assembly region of
human cartilage oligomeric matrix protein (COMP), using a portion of the amino-
terminal end. Other portions of TSP-1 or TSP-2 can be incorporated into the
10 chimeric protein, such as the procollagen homology region of TSP-1 and/or TSP-2.
The last two TSRs of TSP-1 are preferably used because the first TSR has the ability
to activate transforming growth factor β (TGF- β), which stimulates tumor growth.
The COMP assembly domain spontaneously forms a 5-stranded α -helical domain,
allowing for the use of the COMP domain as a tool for pentamerization.

15 Thus, the COMP/TSP-1 construct contains the region for multimerization,
the first type 2 repeat of human COMP (construct encodes amino acids 1-128) and
the second and third TSRs of human TSP-1 (construct encodes amino acids 417-
530). See the Table for active sequences of TSP-1 (taken from chapter 2, "The
Primary Structure of the Thrombospondins" In *The Thrombospondin Gene Family*
20 (J.C. Adams *et al.*, eds.) Springer-Verlag, Heidelberg (1995)). The assembled
protein is a pentamer containing 10 copies of the TSR. Thus, COMP/TSP-1 and
COMP/TSP-2 are expected to be more active than TSP-1 and TSP-2. COMP/TSP-1
and COMP/TSP-2 are expected to be correctly folded and multimeric so that they
better mimic the natural proteins than peptides that are based on the TSR sequence.

25 The first type 2 repeat of COMP includes amino acid residues 73-130, based
on the genomic sequence. The amount of COMP sequence at the 3' end can be
increased or decreased to maximize activity. For example, two or more type 2
repeats of COMP can be included if moving the type 1 repeats of TSP-1 or TSP-2
farther out on the arms of the expressed protein increases its activity. Alternatively,
30 "spacer" sequence not naturally occurring in COMP or in TSP-1 or TSP-2 can be

- added. The COMP/TSP-2 construct contains the same region of COMP and the three TSRs of human TSP-2 (construct encodes amino acids 381-550). When it is assembled to a pentamer this chimeric protein will contain 15 TSRs. Because these proteins are derived from portions of human proteins, they should not be
- 5 immunogenic in humans.

Table: Active Regions of Interest Within Thrombospondin-1

Domain	Sequence	Function
Procollagen homology	NGVQYRN (SEQ ID NO: 8)	Anti-angiogenesis
10 Type 1 repeats	CSVTCG (SEQ ID NO: 9)	Cell binding
	WSXWSXW (SEQ ID NO: 10)	Heparin binding
	GGWSHW (SEQ ID NO: 11)	TGF- β and Fibronectin binding
	RFK	TGF- β activation
	SPWDICSVTCGGGVQKRSR (SEQ ID NO: 12)	Anti-angiogenesis
Type 2 repeats	DVDEC(X) ₆ C(X) ₈ CENTDPGYNCLPC (SEQ ID NO: 13)	Calcium binding

- In one aspect, the invention comprises polynucleotides or nucleic acid molecules that encode chimeric proteins having portions whose amino acid
- 15 sequences are derived from human TSP-1. By the genomic structure, the type 1 repeats of TSP-1 are amino acid residues 359-414 (first), amino acid residues 415-473 (second), and 474-531 (third). In one case, the chimeric protein encoded by the polynucleotides of the invention comprises the second and third type 1 repeats of human TSP-1. Such a chimeric protein may also comprise the procollagen
- 20 homology region and the first type 1 repeat of TSP-1. If amino acid sequences that activate TGF- β are included in the product protein, and are found to reduce anti-angiogenic activity, the RFK sequence can be mutated (to QFK, for example) to a

sequence that does not activate TGF- β , by appropriate manipulations of the nucleic acid molecule or construct encoding the chimeric proteins. In another case, the chimeric proteins encoded by the polynucleotides of the invention are variants of the immediately aforementioned chimeric protein which have activity that is similar in quality and quantity (for example, plus or minus one order of magnitude in an assay) to the anti-angiogenic activity of the protein whose amino acid sequence is represented in Figures 4A and 4B. In another case, the chimeric proteins encoded by polynucleotides of the invention comprise the second and third type 1 repeats of human TSP-1, the multimerization domain of human COMP, and the first type 2 repeat of human COMP. In another case, the chimeric proteins encoded by the polynucleotides of the invention are variants of the immediately aforementioned chimeric protein which have activity that is similar in quality and quantity to the anti-angiogenic activity of the protein whose amino acid sequence is represented in Figures 4A and 4B.

15 In one aspect, the invention comprises polynucleotides or nucleic acid molecules that encode chimeric proteins having portions whose amino acid sequences are derived from human TSP-2. The genomic structure of the human TSP-2 gene, which would provide one way to define the boundaries of the repeats, has not been determined. In one case, the chimeric protein encoded by the polynucleotides of the invention comprises the three type 1 repeats of human TSP-2. In another case, the chimeric proteins encoded by the polynucleotides of the invention are variants of the immediately aforementioned chimeric proteins which have activity that is similar in quality and quantity to the anti-angiogenic activity of the protein whose amino acid sequence is represented in Figures 5A and 5B. In another case, the chimeric protein encoded by polynucleotides of the invention comprises the three type 1 repeats of human TSP-2, and the multimerization domain of human COMP. In another case, the chimeric proteins encoded by the polynucleotides of the invention are variants of the immediately aforementioned chimeric protein which have activity that is similar in quality and quantity to the anti-angiogenic activity of the protein whose amino acid sequence is represented in Figures 5A and 5B.

The polynucleotides of the invention can be made by recombinant methods, can be made synthetically, can be replicated by enzymes in *in vitro* (e.g., PCR) or *in vivo* systems (e.g., by suitable host cells, when inserted into a vector appropriate for replication within the host cells), or can be made by a combination of methods. The
5 polynucleotides of the invention can include DNA and its RNA counterpart.

As used herein, "nucleic acid," "nucleic acid molecule," "oligonucleotide" and "polynucleotide" include DNA and RNA and chemical derivatives thereof, including phosphorothioate derivatives and RNA and DNA molecules having a radioactive isotope or a chemical adduct such as a fluorophore, chromophore or
10 biotin (which can be referred to as a "label"). The RNA counterpart of a DNA is a polymer of ribonucleotide units, wherein the nucleotide sequence can be depicted as having the base U (uracil) at sites within a molecule where DNA has the base T (thymidine).

Isolated nucleic acid molecules or polynucleotides can be purified from a
15 natural source or can be made recombinantly. Polynucleotides referred to herein as "isolated" are polynucleotides purified to a state beyond that in which they exist in cells. They include polynucleotides obtained by methods described herein, similar methods or other suitable methods, and also include essentially pure polynucleotides produced by chemical synthesis or by combinations of biological and chemical
20 methods, and recombinant polynucleotides that have been isolated. The term "isolated" as used herein for nucleic acid molecules, indicates that the molecule in question exists in a physical milieu distinct from that in which it occurs in nature. For example, an isolated polynucleotide may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs, and may even be purified
25 essentially to homogeneity, for example as determined by agarose or polyacrylamide gel electrophoresis or by A_{260}/A_{280} measurements, but may also have further cofactors or molecular stabilizers (for instance, buffers or salts) added.

The invention further comprises the polypeptides encoded by the isolated nucleic acid molecules of the invention. Thus, for example, the invention relates to
30 fusion proteins, comprising a portion of TSP-1 which comprises the second and third type 1 repeats, linked to a second moiety not occurring in TSP-1 as found in

nature. In an analogous manner, the invention relates also to fusion proteins, comprising TSP-2 or a functional portion thereof such as one or more repeat regions as a first moiety, linked to second moiety not occurring in TSP-2 as found in nature. The second moiety can be an amino acid, peptide or polypeptide, and can have enzymatic or binding activity of its own. The first moiety can be in an N-terminal location, C-terminal location or internal to the fusion protein. In one embodiment, the fusion protein comprises the portion of human TSP-1 described immediately above, or human TSP-2 or a portion thereof as the first moiety, and a second moiety comprising a linker sequence and an affinity ligand.

Another aspect of the invention relates to a method of producing a chimeric protein of the invention, or a variant thereof, and to expression systems and host cells containing a vector appropriate for expression of a chimeric protein of the invention. Variants of the chimeric protein include those having amino acid sequences that differ from those sequences in Figures 4A and 4B, and Figures 5A and 5B, wherein those variants have several, such as 5 to 10, 1 to 5, or 3, 2 or 1 amino acids substituted, deleted, or added, in any combination, compared to the sequences in Figures 4A and 4B and Figures 5A and 5B. In one embodiment, variants have silent substitutions, additions and deletions that do not alter the properties and activities of the chimeric protein. Variants can also be modified polypeptides in which one or more amino acid residues are modified, and mutants comprising one or more modified residues.

Proteins and polypeptides described herein can be assessed for their angiogenic activity by using an assay such as those described in Tolsma, S.S. *et al.*, *J. Cell Biol.* 122(2):497-511 (1993), one which measures the migration of bovine adrenal capillary endothelial cells in culture, and one which tests migration of cells into a sponge containing an agent to be tested for activity. A further test for angiogenesis, which can also be adapted also to test anti-angiogenesis activity, is described in Polverini, P.J. *et al.*, *Methods. Enzymol.* 198:440-450 (1991).

Cells that express such a chimeric protein or a variant thereof can be made and maintained in culture, under conditions suitable for expression, to produce protein for isolation. These cells can be procaryotic or eucaryotic. Examples of

procaryotic cells that can be used for expression (as "host cells"; "cell" including herein cells of tissues, cell cultures, cell strains and cell lines) include *Escherichia coli*, *Bacillus subtilis* and other bacteria. Examples of eucaryotic cells that can be used for expression include yeasts such as *Saccharomyces cerevisiae*,

- 5 *Schizosaccharomyces pombe*, *Pichia pastoris* and other lower eucaryotic cells, and cells of higher eucaryotes such as those from insects and mammals. Suitable cells of mammalian origin include primary cells, and cell lines such as CHO, HeLa, 3T3, BHK, COS, 293, and Jurkat cells. Suitable cells of insect origin include primary cells, and cell lines such as SF9 and High five cells. (See, e.g., Ausubel, F.M. *et al.*,
10 eds. *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons Inc., (containing Supplements up through 1998)).

In one embodiment, host cells that produce a recombinant chimeric protein, variant, or portions thereof can be made as follows. A gene encoding a chimeric protein described herein can be inserted into a nucleic acid vector, e.g., a DNA
15 vector, such as a plasmid, virus or other suitable replicon (including vectors suitable for use in gene therapy, such as those derived from adenovirus or others; see, for example Xu, M. *et al.*, *Molecular Genetics and Metabolism* 63:103-109, 1998) can be present in a single copy or multiple copies, or the gene can be integrated in a host cell chromosome. A suitable replicon or integrated gene can contain all or part of
20 the coding sequence for the protein or variant, operably linked to one or more expression control regions whereby the coding sequence is under the control of transcription signals and linked to appropriate translation signals to permit translation. The vector can be introduced into cells by a method appropriate to the type of host cells (e.g., transformation, electroporation, infection). For expression
25 from the gene, the host cells can be maintained under appropriate conditions (e.g., in the presence of inducer, normal growth conditions, etc.). Proteins or polypeptides thus produced can be recovered (e.g., from the cells, the periplasmic space, culture medium) using suitable techniques.

The invention also relates to isolated proteins or polypeptides encoded by
30 nucleic acids of the present invention. Isolated proteins can be purified from a natural source or can be made recombinantly. Proteins or polypeptides referred to

herein as "isolated" are proteins or polypeptides purified to a state beyond that in which they exist in cells and include proteins or polypeptides obtained by methods described herein, similar methods or other suitable methods, and also include essentially pure proteins or polypeptides, proteins or polypeptides produced by chemical synthesis or by combinations of biological and chemical methods, and recombinant proteins or polypeptides which are isolated. Thus, the term "isolated" as used herein, indicates that the polypeptide in question exists in a physical milieu distinct from the cell in which its biosynthesis occurs. For example, an isolated COMP/TSP-1 or COMP/TSP-2 chimeric protein may be purified essentially to homogeneity, for example as determined by PAGE or column chromatography (for example, HPLC), but may also have further cofactors or molecular stabilizers added to the purified protein to enhance activity. In one embodiment, proteins or polypeptides are isolated to a state at least about 75% pure; more preferably at least about 85% pure, and still more preferably at least about 95% pure, as determined by Coomassie blue staining of proteins on SDS-polyacrylamide gels.

Chimeric or fusion proteins can be produced by a variety of methods. For example, a chimeric protein can be produced by the insertion of a TSP gene or portion thereof into a suitable expression vector, such as Bluescript SK +/- (Stratagene), pGEX-4T-2 (Pharmacia), pET-15b, pET-20b(+) or pET-24(+) (Novagen). The resulting construct can be introduced into a suitable host cell for expression. Upon expression, chimeric protein can be purified from a cell lysate by means of a suitable affinity matrix (see e.g., *Current Protocols in Molecular Biology* (Ausubel, F.M. *et al.*, eds., Vol. 2, pp. 16.4.1-16.7.8, containing supplements up through Supplement 44, 1998).

Polypeptides of the invention can be recovered and purified from cell cultures by well-known methods. The recombinant protein can be purified by ammonium sulfate precipitation, heparin-Sepharose affinity chromatography, gel filtration chromatography and/or sucrose gradient ultracentrifugation using standard techniques. Further methods that can be used for purification of the polypeptide include ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction

chromatography, affinity chromatography, hydroxylapatite chromatography and high performance liquid chromatography. Known methods for refolding protein can be used to regenerate active conformation if the polypeptide is denatured during isolation or purification.

5 The method to construct genes encoding COMP/TSP-1 or COMP/TSP-2 hybrid proteins can be applied more broadly to produce polynucleotides, and vectors and host cells comprising such polynucleotides, wherein the polynucleotides encode COMP/endostatin, COMP/angiostatin, COMP/platelet factor 4, or COMP/prolactin, for example. In each case, a portion of a polynucleotide known to encode full-
10 length human endostatin, angiostatin, platelet factor 4 (GenBank Accession No. M25897) or prolactin (GenBank Accession No. V00566), can be chosen for cloning into a COMP cDNA as illustrated herein for COMP/TSP-1 and COMP/TSP-2 DNA constructs. Thus, the invention also includes COMP/endostatin, COMP/angiostatin, COMP/platelet factor 4, and COMP/prolactin chimeric proteins encoded by such
15 nucleic acid constructs. See Figure 6 for a schematic representation of the structure of COMP/endostatin.

 In addition, a portion of the endostatin, angiostatin, platelet factor 4 or prolactin coding regions, wherein that portion encodes a polypeptide having anti-angiogenic activity, can be added to or incorporated into a DNA construct encoding
20 COMP/TSP-1, such that a TSP-1-derived polypeptide and a polypeptide derived from endostatin, angiostatin, platelet factor 4 or prolactin are produced fused together in tandem on the same "arm" of the "5-armed" COMP-multimerized pentamer. Different expression constructs can be introduced into the same host cells such that two or more chimeric protein "arms" of different types (e.g.,
25 COMP/angiostatin and COMP/TSP-1 or COMP/TSP-2) are joined at the COMP multimerization domain.

 Chimeric protein antiangiogenic agents can be used, for example, after surgery or radiation to prevent recurrence of metastases, in combination with conventional chemotherapy, immunotherapy, or various types of gene therapy not
30 necessarily directed against angiogenesis.

Construction of COMP/TSP-1P Expression Vectors

Expression vectors that can be used to produce COMP/TSP-1P, a chimeric protein that includes the procollagen homology region (see Figure 6), can be produced from two distinct cDNAs. The COMP portion is identical to that in the Examples described herein. For TSP-1, a new forward primer (GAT GAC GTC ACT GAA GAG AAC AAA GAG) (SEQ ID NO: 14) and the same reverse primer as described in the Examples can be used to produce a PCR product that is approximately 750 base pairs in size and has an AatII restriction endonuclease site at the 5' end and an XbaI restriction endonuclease site at the 3' end. The product codes for amino acids 284-530 and includes the procollagen homology region (exons 6 and 7) and type 1 repeats. If inclusion of the TGF- β activating sequence (RFK) that is in the first type 1 repeat is found to reduce the antitumor activity, this sequence will be mutated to an inactive sequence (QFK, for example) using an oligonucleotide-directed mutagenesis kit (Amersham). The COMP/TSP-1P expression vector can be constructed by cutting the PCR product with AatII and XbaI and cloning it into the COMP cDNA cut with the same enzymes. The protein can be expressed using the methods that have been described for COMP/TSP-1 and COMP/TSP-2.

Construction of COMP/Endostatin Expression Vectors

The strategy for making multimers of the TSP-1 and TSP-2 can be used to make multimers of other anti-angiogenic proteins. For example, if the active region of endostatin is prepared by PCR and cloned into the COMP cDNA, a pentameric structure of endostatin can be made when this construct is expressed (O'Reilly M.D., *et al.*, *Cell* 88:277-285, (1997)). In addition, if the COMP/TSP-1 and the COMP/endostatin genes are expressed concurrently within the same cells, mixed pentamers of COMP/TSP-1 and COMP/endostatin subunits are made. The mixed multimer allows simultaneous treatment with the two reagents by delivery of a single therapeutic. An additive or synergistic effect of the two agents may significantly increase the efficacy of this reagent as compared to that of each reagent alone. For example, combination therapy with angiostatin and endostatin has eradicated tumors in mice (Boehm, T. *et al.*, *Nature* 390:404-407, 1997).

The cDNA for endostatin can be prepared by PCR of liver cDNA or from an isolated cDNA clone for collagen XVIII (GenBank accession no. L22548). The human endostatin cDNA can be produced by PCR with the forward primer GAT GAC GTC CAC AGC CAC CGC G (SEQ ID NO: 15) and the reverse primer GAT
5 TCT AGA CTA CTT GGA GGC AGT CAT G (SEQ ID NO: 16). The resulting PCR product is approximately 560 base pairs and encodes amino acids 1 to 184 of human endostatin (Sasaki, T., *et al.*, *EMBO J.*, 17:4249-4256, 1998). The COMP/endostatin expression vector can be constructed by cutting the PCR product with AatII and XbaI, and cloning it into cDNA cut with the same enzymes. The
10 protein can be expressed using the methods that have been described herein for COMP/TSP-1 and COMP/TSP-2. Angiostatin, as it was isolated from mice bearing Lewis lung carcinoma, includes the first four kringle domains of plasminogen (amino acids 98-440) (O'Reilly, M.S., *et al.*, *Cell* 79:315-328, 1994). It should be noted that smaller constructs that contain fewer kringle domains should also be
15 active based on published data (Griscelli, F., *et al.*, *Proc. Natl. Acad. Sci. USA* 95:6367-6372, 1998). A 16,000 dalton fragment of prolactin and platelet factor 4 have also been reported to inhibit angiogenesis (Clapp, C. *et al.*, *Endocrinology* 133:1292-1299, 1993; Gupta, S.K., *et al.*, *Proc. Natl. Acad. Sci. USA* 92:7799-7803, 1995).

20 Also included in the inventions are compositions containing, as a biological ingredient, an anti-angiogenic chimeric protein, or a variant thereof to inhibit angiogenesis in mammalian tissues, and use of such compositions in the treatment of diseases and conditions characterized by, or associated with, angiogenic activity. Such methods can involve administration by oral, topical, injection, implantation,
25 sustained release, or other delivery methods that bring one or more anti-angiogenic chimeric proteins in contact with cells whose growth is to be inhibited.

The present invention includes a method of treating an angiogenesis-mediated disease with a therapeutically effective amount of one or more anti-angiogenic chimeric proteins. Angiogenesis-mediated diseases can include, but are
30 not limited to, cancers, solid tumors, tumor metastasis, benign tumors (*e.g.*, hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic

granulomas), rheumatoid arthritis, psoriasis, ocular angiogenic diseases (*e.g.*, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis), Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, and wound granulation.

"Cancer" means neoplastic growth, hyperplastic or proliferative growth or a pathological state of abnormal cellular development and includes solid tumors, non-solid tumors, and any abnormal cellular proliferation, such as that seen in leukemia. As used herein, "cancer" also means angiogenesis-dependent cancers and tumors, *i.e.*, tumors that require for their growth (expansion in volume and/or mass) an increase in the number and density of the blood vessels supplying them with blood. "Regression" refers to the reduction of tumor mass and size. As used herein, the term "therapeutically effective amount" means the total amount of each active component of the composition or method that is sufficient to show a meaningful benefit to a treated human or other mammal, *i.e.*, treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. More specifically, for example, a therapeutically effective amount of an anti-angiogenic chimeric protein can cause a measurable reduction in the size or numbers of tumors, or in their rate of growth or multiplication, compared to untreated tumors. Other methods of assessing a "therapeutically effective amount," can include the result that blood vessel formation is measurably reduced in treated tissues compared to untreated tissues.

One or more anti-angiogenic chimeric proteins may be used in combination with other compositions and procedures for the treatment of diseases. For example, a tumor may be treated conventionally with surgery, radiation, chemotherapy, or immunotherapy, combined with anti-angiogenic chimeric proteins, and then anti-angiogenic chimeric proteins may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize and inhibit the growth of any residual primary tumor.

The compositions may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment, such as

chemotherapeutic or radioactive agents. Such additional factors and/or agents may be included in the composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Additionally, administration of the composition of the present invention may be administered concurrently with other
5 therapies, *e.g.*, administered in conjunction with a chemotherapy, immunotherapy or radiation therapy regimen.

The angiogenesis-modulating composition of the present invention may be a solid, liquid or aerosol and may be administered by any known route of administration. Examples of solid compositions include pills, creams, and
10 implantable dosage units. The pills may be administered orally, the therapeutic creams may be administered topically. The implantable dosage unit may be administered locally, for example at a tumor site, or may be implanted for systemic release of the angiogenesis-modulating composition, for example subcutaneously. Examples of liquid composition include formulations adapted for injection
15 subcutaneously, intravenously, intraarterially, and formulations for topical and intraocular administration. Examples of aerosol formulation include inhaler formulation for administration to the lungs.

The anti-angiogenic chimeric proteins can be provided as isolated and substantially purified proteins in pharmaceutically acceptable formulations
20 (including aqueous or nonaqueous carriers or solvents) using formulation methods known to those of ordinary skill in the art. These formulations can be administered by standard routes. In general, the combinations may be administered by the topical, transdermal, intraperitoneal, intracranial, intracerebroventricular, intracerebral, intravaginal, intrauterine, oral, rectal or parenteral (*e.g.*, intravenous, intraspinal,
25 subcutaneous or intramuscular) route. In addition, the anti-angiogenic chimeric proteins may be incorporated into biodegradable polymers allowing for sustained release of the compound, the polymers being implanted in the vicinity of where drug delivery is desired, for example, at the site of a tumor, or implanted so that the anti-angiogenic chimeric proteins is slowly released systemically. Osmotic minipumps
30 may also be used to provide controlled delivery of high concentrations of anti-angiogenic chimeric proteins through cannulae to the site of interest, such as directly

into a growth or into the vascular supply to that growth. The biodegradable polymers and their use are described, for example, in detail in Brem *et al.* (1991) (*J. Neurosurg.* 74:441-446), which is hereby incorporated by reference in its entirety.

As used herein, the terms "pharmaceutically acceptable," as it refers to
5 compositions, carriers, diluents and reagents, represents that the materials are capable of administration to or upon a mammal with a minimum of undesirable physiological effects such as nausea, dizziness, gastric upset and the like. The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art and need not be limited
10 based on formulation. Typically, such compositions are prepared as injectables either as liquid solutions or suspensions, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified, for example, in liposomes.

The dosage of the anti-angiogenic chimeric proteins of the present invention
15 will depend on the disease state or condition being treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. It is to be understood that the present invention has application for both human and veterinary use. The methods of the present invention contemplate single as well as multiple administrations, given either simultaneously
20 or over an extended period of time.

The present invention also encompasses gene therapy whereby a polynucleotide encoding one or more anti-angiogenic chimeric proteins or one or more variants thereof, is introduced and regulated in a patient. Various methods of transferring or delivering DNA to cells for expression of the gene product protein,
25 otherwise referred to as gene therapy, are disclosed in *Gene Transfer into Mammalian Somatic Cells in Vivo*, N. Yang (1992) *Crit. Rev. Biotechnol.* 12(4):335-356, which is hereby incorporated by reference. Gene therapy encompasses incorporation of DNA sequences into somatic cells or germ line cells for use in either ex vivo or in vivo therapy. Gene therapy can function to replace genes,
30 augment normal or abnormal gene function, and to combat infectious diseases and other pathologies.

Strategies for treating these medical problems with gene therapy include therapeutic strategies such as identifying the defective gene and then adding a functional gene to either replace the function of the defective gene or to augment a slightly functional gene; or prophylactic strategies, such as adding a gene for the product protein that will treat the condition or that will make the tissue or organ more susceptible to a treatment regimen. For example, a gene encoding an anti-angiogenic chimeric protein may be inserted into tumor cells of a patient and thus inhibit angiogenesis.

Gene transfer methods for gene therapy fall into three broad categories: physical (e.g., electroporation, direct gene transfer and particle bombardment), chemical (e.g., lipid-based carriers, or other non-viral vectors) and biological (e.g., virus-derived vector and receptor uptake). For example, non-viral vectors may be used which include liposomes coated with DNA. Such liposome/DNA complexes may be directly injected intravenously into the patient. It is believed that the liposome/DNA complexes are concentrated in the liver where they deliver the DNA to macrophages and Kupffer cells. These cells are long lived and thus provide long term expression of the delivered DNA. Additionally, vectors or the "naked" DNA of the gene may be directly injected into the desired organ, tissue or tumor for targeted delivery of the therapeutic DNA.

In vivo gene transfer involves introducing the DNA into the cells of the patient when the cells are within the patient. Methods include using virally mediated gene transfer using a noninfectious virus to deliver the gene in the patient or injecting naked DNA into a site in the patient and the DNA is taken up by a percentage of cells in which the gene product protein is expressed. Additionally, the other methods described herein, such as use of a "gene gun," may be used for *in vitro* insertion of anti-angiogenic chimeric proteins DNA or anti-angiogenic chimeric proteins regulatory sequences.

Chemical methods of gene therapy may involve a lipid based compound, not necessarily a liposome, to transfer the DNA across the cell membrane. Lipofectins or cytofectins, lipid-based positive ions that bind to negatively charged DNA, make a complex that can cross the cell membrane and provide the DNA into the interior of

the cell. Another chemical method uses receptor-based endocytosis, which involves binding a specific ligand to a cell surface receptor and enveloping and transporting it across the cell membrane. The ligand binds to the DNA and the whole complex is transported into the cell. The ligand gene complex is injected into the blood stream
5 and then target cells that have the receptor will specifically bind the ligand and transport the ligand-DNA complex into the cell.

Many gene therapy methodologies employ viral vectors to insert genes into cells. For example, altered retrovirus vectors have been used in *ex vivo* methods to introduce genes into peripheral and tumor-infiltrating lymphocytes, hepatocytes,
10 epidermal cells, myocytes, or other somatic cells. These altered cells are then introduced into the patient to provide the gene product from the inserted DNA.

Viral vectors have also been used to insert genes into cells using *in vivo* protocols. To direct the tissue-specific expression of foreign genes, *cis-acting* regulatory elements or promoters that are known to be tissue-specific can be used.
15 Alternatively, this can be achieved using *in situ* delivery of DNA or viral vectors to specific anatomical sites *in vivo*. For example, gene transfer to blood vessels *in vivo* was achieved by implanting *in vitro* transduced endothelial cells in chosen sites on arterial walls. The virus infected surrounding cells which also expressed the gene product. A viral vector can be delivered directly to the *in vivo* site, by a catheter for
20 example, thus allowing only certain areas to be infected by the virus, and providing long-term, site specific gene expression. *In vivo* gene transfer using retrovirus vectors has also been demonstrated in mammary tissue and hepatic tissue by injection of the altered virus into blood vessels leading to the organs.

Viral vectors that have been used for gene therapy protocols include but are
25 not limited to, retroviruses, other RNA viruses such as poliovirus or Sindbis virus, adenovirus, adeno-associated virus, herpes viruses, SV40, vaccinia and other DNA viruses. Replication-defective murine retroviral vectors have been widely utilized gene transfer vectors.

Carrier mediated gene transfer *in vivo* can be used to transfect foreign DNA
30 into cells. The carrier-DNA complex can be conveniently introduced into body fluids or the bloodstream and then site-specifically directed to the target organ or

tissue in the body. Both liposomes and polycations, such as polylysine, lipofectins or cytofectins, can be used. Liposomes can be developed which are cell specific or organ specific and thus the foreign DNA carried by the liposome will be taken up by target cells. Injection of immunoliposomes that are targeted to a specific receptor on certain cells can be used as a convenient method of inserting the DNA into the cells bearing the receptor. Another carrier system that has been used is the asialoglycoprotein/polylysine conjugate system for carrying DNA to hepatocytes for *in vivo* gene transfer.

The gene therapy protocol for transfecting anti-angiogenic chimeric proteins into a patient may either be through integration of a gene encoding an anti-angiogenic chimeric protein into the genome of the cells, into minichromosomes or as a separate replicating or non-replicating DNA construct in the cytoplasm or nucleoplasm of the cell. Anti-angiogenic chimeric proteins expression may continue for a long-period of time or may be reinjected periodically to maintain a desired level of the anti-angiogenic chimeric proteins protein in the cell, the tissue or organ or a determined blood level.

EXAMPLES

Example 1: Construction of COMP/TSP-1 and COMP/TSP-2

The chimeric expression vectors have been produced from three distinct cDNAs. The first is a clone for human cartilage oligomeric matrix protein (COMP) and was isolated from a λ gt11 chondrocyte cDNA library (Doege, K.J., *et al.*, *J. Biol. Chem.* 266:894-902 (1991)). This is an almost full-length clone for the COMP mRNA that only lacks a small region of the 5'-untranslated region. This clone (hCOMP-95) was used previously to determine the sequence of human COMP (GenBank Accession No. L32137; *Genomics*, 24:435-439 (1994)).

The second cDNA was produced using the polymerase chain reaction (PCR) with the human thrombospondin-1 (TSP-1) gene as the template. The TSP-1 clones were isolated from a human endothelial cell library (*J. Cell Biol.* 103:1635-1648

(1986)). The forward primer (GAT GAC GTC GAT GGT GGC TGG AGC CAC) (SEQ ID NO: 17) and the reverse primer (GAT CTA GAT TGG ACA GTC CTG CTT G) (SEQ ID NO: 18) produce a PCR product that is approximately 354 basepairs in size and has an Aat II restriction endonuclease site at the 5' end and an Xba I restriction endonuclease site at the 3' end. The PCR product encodes amino acids 417 to 530 and includes the second and third type 1 repeats of TSP-1 (see Figure 1 for the numbering of amino acids in TSP-1). The coding sequence for the first type 1 repeat was not included in the PCR product, by design, because it contains an RFK sequence that has been shown to activate TGF- β . This activity is not required to inhibit angiogenesis and it may produce unwanted secondary effects on numerous cell types. Vectors that include the first type 1 repeat can be constructed, using the same approach, if this region is found to enhance the antiangiogenic activity or other activities.

The third cDNA was produced by PCR with a human heart cDNA library (catalog no. 936208 from Stratagene, LaJolla, CA) as the template. The forward primer (GAT GAC GTC GAG GAG GGC TGG TCT CCG) (SEQ ID NO: 19) and the reverse primer (GAT CTA GAC ACG GGG CAG CTC CTC TTG) (SEQ ID NO: 20) produced a PCR product that is approximately 520 base pairs in size and has an Aat II restriction endonuclease site at the 5' end and an Xba I restriction endonuclease site at the 3' end. The PCR product codes for amino acids 381 to 550 of TSP-2 and, includes all three type 1 repeats of TSP-2 (see Figure 2 for numbering of amino acids in TSP-2). The sequence of the PCR primers was based on the human TSP-2 sequence in the GenBank database (Accession No. L12350). The sequences of the PCR products were determined to establish that mutations that affect the amino acid sequence had not been introduced during the PCR.

The COMP/TSP-1 and COMP-TSP-2 expression vectors were constructed by cutting the PCR products with Aat II and Xba I and subcloning them into the COMP cDNA vector [derived from Bluescript (Stratagene, La Jolla, CA)] cut with the same enzymes. The portion of COMP that was retained includes the signal sequence, the regions required for pentamerization and the first type 2 repeat (amino acids 1 to 128 on the enclosed sequence; Figure 3). Since there was an internal Aat

II site in the TSP-2 PCR product, it had to be cloned into the vector in two steps. A 430 basepair Aat II/Xba I fragment of the TSP-2 PCR product was subcloned into the vector containing the portion of COMP as a first step. The resulting subclone was cut with Aat II, and a 90 base pair Aat II fragment of the PCR product was
5 ligated into the expression vector. The final forms of the cDNAs were confirmed to have the predicted structure by nucleotide sequencing. They were then cut with Eco R1 and Xba I and ligated into the pcDNA 3.1 (Invitrogen; Carlsbad, CA) vector cut with the same enzymes. The DNA sequences of COMP/TSP-1 and COMP/TSP-2 are shown in Figures 4A and 4B and Figures 5A and 5B, respectively. The
10 predicted molecular weights of the subunits of COMP/TSP-1 and COMP/TSP-2 should be approximately 24,200 and 30,000, respectively. The fully assembled COMP/TSP-1 and COMP/TSP-2 proteins should be 121,000 Da and 150,000 Da, respectively. The amino acid sequences of these proteins are shown in Figures 4A and 4B and Figures 5A and 5B, respectively.

15 Example 2: Production of Isolated COMP/TSP-1 and COMP/TSP-2

To express these chimeric proteins, the expression vectors can be transfected into human kidney 293 cells using the Lipofectin protocol (Gibco Laboratories). The cells can be selected with Zeocin and individual clones can be grown. The secretion of COMP/TSP-1 and COMP/TSP-2 can be monitored with western
20 blotting using polyclonal antibodies to the region of COMP that is present in both expressed proteins. These antibodies have been produced by immunizing rabbits with a synthetically produced peptide, having an amino acid sequence derived from the N-terminal end of COMP, linked to a carrier protein. The amino acid sequence of the peptide is: SDLGPQMLRELQETN (SEQ ID NO: 21). A clone that
25 expresses high levels of the protein can be grown in large volume flasks and in serum free media.

Example 3: Inhibition of Tumor Growth by COMP/TSP-1

A cDNA of thrombospondin-1 (TSP-1) containing the second and third type-1 repeats and the COMP assembly sequence (COMP/TSP-1) was produced by PCR

using constructs derived as above as template, and was cloned into the expression vector pNeo (Invitrogen, Carlsbad, CA). Both the resulting COMP/TSP-1 construct and the unaltered vector alone were transfected into the human squamous carcinoma cell line A431 (Streit, M., *et al.*, *American Journal of Pathology* 155:441-452, 5 1999), and positive clones were selected using Geneticin at a concentration of 800 $\mu\text{g/ml}$. The growth curves of positive clones were determined over an 8 day period. Clones of pNeo- and COMP/TSP-1 construct-transfected cells that had similar growth curves were selected to test the effect of the chimeric protein on tumor growth in nude mice. A total of five mice per group were injected intradermally at 10 the shoulders with 5×10^6 cells per site, two sites per mouse. Every week the tumors were measured with calipers. At three weeks, the mice were sacrificed and the tumors were removed for further studies. As can be seen from Figure 7, expression of COMP/TSP-1 caused inhibition of the growth of the tumors in this model.

15 All references (e.g., journal articles, books, published patent applications and patents, etc.) cited herein are hereby incorporated by reference.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without 20 departing from the spirit and scope of the invention as defined by the appended claims.

CLAIMS

What is claimed is:

1. A nucleic acid molecule encoding a chimeric protein comprising the second
and third type 1 repeats of human TSP-1, but not the TGF- β activation
5 region of human TSP-1.
2. A nucleic acid molecule encoding a chimeric protein comprising the
multimerization domain of human COMP, the first type 2 repeat of human
COMP, and the second and third type 1 repeats of human TSP-1.
3. A nucleic acid molecule encoding a chimeric protein comprising the
10 multimerization domain of human COMP, the first type 2 repeat of human
COMP, and the second and third type 1 repeats of human TSP-1, but not the
TGF- β activation region of human TSP-1.
4. A nucleic acid molecule encoding a chimeric protein comprising the
multimerization domain of human COMP, the procollagen homology region
15 of TSP-1, and the first, second, and third type 1 repeats of human TSP-1.
5. A nucleic acid molecule encoding a chimeric protein comprising the
multimerization domain of human COMP, the procollagen homology region
of TSP-1, and the first, second, and third type 1 repeats of human TSP-1, but
not the TGF- β activation region of human TSP-1.
- 20 6. A nucleic acid molecule encoding a chimeric protein comprising the
multimerization domain of human COMP and a portion of human endostatin,
wherein the chimeric protein has anti-angiogenic activity.

7. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP and a portion of human angiostatin, wherein the chimeric protein has anti-angiogenic activity.
8. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP and a portion of human prolactin, wherein the chimeric protein has anti-angiogenic activity.
9. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP and a portion of human platelet factor 4, wherein the chimeric protein has anti-angiogenic activity.
10. 10. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP, the procollagen homology region, and the first, second, and third type 1 repeats of human TSP-1.
11. A nucleic acid molecule encoding a protein having the amino acid sequence SEQ ID NO: 5.
- 15 12. A vector comprising nucleic acid encoding a chimeric protein comprising the second and third type 1 repeats of human TSP-1 but not the TGF- β activation region of human TSP-1.
13. A host cell comprising the vector of Claim 12.
14. A vector comprising nucleic acid encoding a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1.
- 20 15. A host cell comprising the vector of Claim 14.

16. A method for producing a chimeric protein which comprises the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1, said method comprising maintaining the host cell of Claim 15 under conditions suitable for expression of said nucleic acid, whereby said protein is produced.
17. The method of Claim 16 further comprising isolating the chimeric protein.
18. A vector comprising nucleic acid encoding a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1, but not the TGF- β activation region of human TSP-1.
19. A host cell comprising the vector of Claim 18.
20. A method for producing a chimeric protein which comprises the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1, but not the TGF- β activation region of human TSP-1, said method comprising maintaining the host cell of Claim 19 under conditions suitable for expression of said nucleic acid, whereby said protein is produced.
21. The method of Claim 20 further comprising isolating the chimeric protein.
22. A vector comprising nucleic acid encoding a chimeric protein comprising the multimerization domain of human COMP, the procollagen homology region, and the first, second, and third type 1 repeats of human TSP-1.
23. A vector comprising nucleic acid encoding a protein having the amino acid sequence SEQ ID NO: 5.

24. A host cell comprising the vector of Claim 23.
25. A chimeric protein comprising the second and third type 1 repeat of human TSP-1, but not the TGF- β activation region of human TSP-1.
26. A chimeric protein comprising the multimerization domain of human
5 COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1.
27. A chimeric protein comprising the multimerization domain of human
10 COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1, but not the TGF- β activation region of human TSP-1.
28. A chimeric protein comprising the multimerization domain of human COMP, the procollagen homology region of TSP-1, and the first, second, and third type 1 repeats of human TSP-1.
29. A chimeric protein comprising the multimerization domain of human COMP
15 and a portion of human endostatin, wherein the chimeric protein has anti-angiogenic activity.
30. A chimeric protein comprising the multimerization domain of human COMP and a portion of human angiostatin, wherein the chimeric protein has anti-angiogenic activity.
- 20 31. A chimeric protein comprising the multimerization domain of human COMP and a portion of human prolactin, wherein the chimeric protein has anti-angiogenic activity.

32. A chimeric protein comprising the multimerization domain of human COMP and a portion of human platelet factor 4, wherein the chimeric protein has anti-angiogenic activity.
33. A protein having the amino acid sequence SEQ ID NO: 5.
- 5 34. An isolated nucleic acid molecule encoding a chimeric protein comprising the three type 1 repeats of human TSP-2.
35. A vector comprising nucleic acid encoding a chimeric protein comprising the three type 1 repeats of human TSP-2.
36. A host cell comprising the vector of Claim 35.
- 10 37. A method for producing a chimeric protein which comprises the three type 1 repeats of human TSP-2, said method comprising maintaining the host cell of Claim 36 under conditions suitable for expression of said nucleic acid, whereby said protein is produced.
38. The method of Claim 37 further comprising isolating the chimeric protein.
- 15 39. A nucleic acid molecule encoding a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the three type 1 repeats of human TSP-2.
40. A vector comprising isolated nucleic acid encoding a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the three type 1 repeats of human TSP-2.
- 20 41. A host cell comprising the vector of Claim 40.

42. A method for producing a chimeric protein which comprises the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the three type 1 repeats of human TSP-2, said method comprising maintaining the host cell of Claim 41 under conditions suitable for expression of said nucleic acid, whereby said protein is produced.
43. The method of Claim 42 further comprising isolating the chimeric protein.
44. A nucleic acid molecule encoding a protein having the amino acid sequence SEQ ID NO: 7.
45. A vector comprising nucleic acid encoding a protein having the amino acid sequence SEQ ID NO: 7.
46. A host cell comprising the vector of Claim 45.
47. A chimeric protein comprising the three type 1 repeats of human TSP-2.
48. A chimeric protein comprising the procollagen homology region of TSP-2 and the three type 1 repeats of human TSP-2.
49. A chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the three type 1 repeats of human TSP-2.
50. A protein having the amino acid sequence SEQ ID NO: 7.
51. A method for inhibiting angiogenesis in a human or other mammal, the method comprising administering to the human or other mammal a therapeutically effective amount of an anti-angiogenic chimeric protein.

52. The method of Claim 51 wherein the anti-angiogenic chimeric protein is selected from the group consisting of:
- a) a chimeric protein comprising the second and third type 1 repeats of human TSP-1;
 - 5 b) a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and third type 1 repeats of human TSP-1;
 - c) a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the second and
10 third type 1 repeats of human TSP-1, but not the TGF- β activation region of human TSP-1;
 - d) a chimeric protein comprising the multimerization domain of human COMP, the procollagen region, and the first, second, and third type 1 repeats of human TSP-1; and
 - 15 e) a chimeric protein comprising the three type 1 repeats of human TSP-2; and (6) a chimeric protein comprising the multimerization domain of human COMP, the first type 2 repeat of human COMP, and the three type 1 repeats of human TSP-2.
53. The method of Claim 51 wherein the anti-angiogenic protein is administered
20 locally at the site of one or more growths.

1/9

human thrombospondin-1

1 HRIPESGGDSVFDJFELTGAARKSGRRLLVKGPDSPSPAFRIEDANLIPPVPDDKFDL
 61 VDAVRTEKGFLLASLRQMKTGRGTLALERKDHSGQVSVNCGKAGTLDLSLTVQGGKQ
 121 HVVSVEALLATGQWKSITLFVQEDRAQLYIDCEKMEAEADVPIQSVFTRDLASIALRL
 181 IAKGGVNDHFQGVQLQNVRFVFGTTPEDILRNKGCSSSTSVLLTLDHVVVNGSSPAIRTN
 241 IGHKTKDLQAICGISCELSM
 263 VLEIRGLRTIVTTLQDSIRKVTENKEIAHEIRRPPLCYHNGVQYRNNE
 312 EWTVDSCTECHCQNSVTICKVSCPIMPCHDAVTPDGECCPCWPSPDSA
 361 DDGWSFWSEWTSCTSCGNGIQQRGRSCDSIHR-----CEGSSVQTRTCHIQECDKRFKQ
 417 DGGWSHWSFWSSCSVTGQGVITRIRLCHSPSPQMNGKPCGEARETKACKKDACPI
 474 HGGWGPWSFWIDCSVTGCGGVQKRSLCQWPTPQFGGKDCVGDVTENQICNKQDCPT
 531 DGCLSNP---CFAGV---KCT---SYDGSWKCGACPPGYSG-----NGIQCTDV
 572 DECKEVPDACFHNGEHCEN-----TDPGYHCLPCPPRPTGSPFGQGVENATANKQVCKPR
 630 HPCTDGTDCNKHA---KCHYLGHYSDPMYRC-ECKPGYAG-----NGIICGE
 674 DTDLGGWPHLEHLVGVAMIAITYHCKK
 698 DRCPLPWSGQEDYDKGIGDACUD--DDDHDKIPDDR
 734 DRCPPHYHVAQYDYDRDDVGDRC
 757 DRCFYHHHPDQADTDNRHGEDACAA--DIDGDDGILHER
 793 DRCQVYVRVDQRDTMDGVGDQC
 816 DRCPLHHHPQLDSDSDRIGDTCDNNQDIDEDGHQNRLL
 854 DRCPYVPHARQADHDKGGDACDH--DDNDGIFDOK
 890 DRCRLVPHPDQKDSGDRGSDACKD--DFDDDSVPDID
 926 DICPERVDISETFRRFQMIPLDPKGTSDNDPHVVVRHQKELVQTVNCDPGLAVGYDEF
 986 NAVDFSGTFFINTERDDDYAGFVFGYQSSSRFYVVMKQVTSYWDNNPTRAQQYSGLSV
 1046 KVVHSTTGPGGELRNALWHTGNTPGQVRLWHDPHHIGWKDFTAYRWRLSHRPKTGFLRV
 1106 VMYEGKKIMADSGPIYDFTYAGGRIGLVFVSQEHVFFSDIKYECRDP

NH₂
 P
 type 1
 type 2
 type 3
 COOH

FIG. 1

2/9

human thrombospondin-2

1 MVRLVLLALLVWPSTQAGHQDKDTTDLFSISINHKKTIGAKQFRGPDGVPAYRFVRF
 61 DYIPPVNADDLISKITKIMRQKEGFFLTAQLKQDCKSRGTLLEGLSQRQFEIVSNGP
 121 ADTLDLTYNIDGTRHVVSLIEDVGLADSQWKNVTQVAGETYSLHVGCGLIGPVALDEPFY
 181 ENLQAEKSRMYVAKGSARESHFRGLLQNVHLVENSVEDLSKKGCCQGGAGAEINAISEN
 241 TETLRLLGPHVTTTEYVGPSSERRPEVCSCEELGMM
 277 VQELSGLIHVLVHQLSENLRKRVSNNDHQFLNELIGGPPKTRQMSACWQDGRFFA~~QDE~~
 332 TWVVDSC~~TTCTCKKFKTICHQITCP~~ATCASPSFVEGECPCSLHSVDG
 381 EEGSWPAEWTQCSVTGSGTQQRGRSCDVTSNT-----CLGPSIQTRACSLSKCDTRIRQ
 437 DGGWSHWSPWSSCSVTCCGV~~QDITRIR~~LCNSPVPQMGKKCKGSGRETAKCQGAPCPI
 494 DGRWSPWSFWSACTVTCAGGIRERTRVCHSPPEQYGGKACVGDVQERQMCNKRSCPV
 551 DGCLSNP---CFPGA---QCS---SFPDGSWSGGFCPPVGF~~LG~~-----~~(Y)GT~~HCCEDL
 592 DECALVPDLCFSTSKVPRCVN---TQPGFHCLPCPPRYRGNQPVGVGLEAAKTEKQVCEPE
 650 NPKCKDKTHCHKHA---ECIYLGHFS~~DP~~MYKCE-CQTGYAG-----DGLICGE
 694 DSDLDGWP~~PH~~LNLVCA~~T~~THATYHC~~IK~~
 718 DHCPLPHSGQEDFDKDGIGDADCD--DDNDGVTDEK
 748 DNCQLLENPRQADYDKDEVDRC
 777 DHCPLYVHNPAQIDTDNNGEGDACS~~V~~--DIDGDDVFRER
 813 DHCPLYVYNTDQRTDGDGVGDHC
 836 DHCPLVHN~~PQ~~QTDVDNDLVGDQCDN~~NE~~DI~~DD~~DGHHQ~~HHQ~~
 874 DHCPLYISNANQADH~~DR~~DGGD~~AC~~DP--DDNDGVPDDR
 910 DHCRLVHNPDQEDLDG~~GG~~AG~~DI~~CKD--DFDNDRI~~PD~~ID
 946 DVCPENNATSETDFRN~~FQ~~MYPLDPKGT~~TI~~DPH~~W~~VIHQKELVQTANS~~DP~~GIAVGFDEF
 1006 GSVDFSGTFYVNTDRDD~~DD~~YAGFVFGYQSSSFYV~~V~~MMKQV~~VT~~QTYWEDQ~~PT~~RAYGYS~~GS~~VL
 1066 KVV~~Q~~STGTGTEHLRNALWHTGNTPGQV~~RT~~LWHDPRHIGNKDY~~T~~AYR~~WH~~LT~~HR~~PKTYIRV
 1126 LVHEGKQVHADSGPIYDQTYAGGRGL~~FL~~VSQEMV~~Y~~FS~~DL~~KYEC~~RD~~I

FIG. 2

FIG. 3

4/9

CAGCACCCAG CTCGCCGCCA CCGCC ATG GTC CCC GAC ACC GCC TGC GTT CTT	52
Met Val Pro Asp Thr Ala Cys Val Leu	
1 5	
CTG CTC ACC CTG GCT GCC CTC GGC GCG TCC GGA CAG GGC CAG AGC CCG	100
Leu Leu Thr Leu Ala Ala Leu Gly Ala Ser Gly Gln Gly Gln Ser Pro	
10 15 20 25	
TTG GGC TCA GAC CTG GGC CCG CAG ATG CTT CGG GAA CTG CAG GAA ACC	148
Leu Gly Ser Asp Leu Gly Pro Gln Met Leu Arg Glu Leu Gln Glu Thr	
30 35 40	
AAC GCG GCG CTG CAG GAC GTG CCG GAC TGG CTG CCG CAG CAG GTC AGG	196
Asn Ala Ala Leu Gln Asp Val Arg Asp Trp Leu Arg Gln Gln Val Arg	
45 50 55	
GAG ATC ACC TTC CTG AAA AAC ACG GTG ATG GAG TGT GAC GCG TGC GGG	244
Glu Ile Thr Phe Leu Lys Asn Thr Val Met Glu Cys Asp Ala Cys Gly	
60 65 70	
ATG CAG CAG TCA GTA CGC ACC GGC CTA CCC AGC GTG CCG CCC CTG CTC	292
Met Gln Gln Ser Val Arg Thr Gly Leu Pro Ser Val Arg Pro Leu Leu	
75 80 85	
CAC TGC GCG CCC GGC TTC TGC TTC CCC GGC GTG GCC TGC ATC CAG ACG	340
His Cys Ala Pro Gly Phe Cys Phe Pro Gly Val Ala Cys Ile Gln Thr	
90 95 100 105	
GAG AGC GGC GGC CGC TGC GGC CCC TGC CCC GCG GGC TTC ACG GGC AAC	388
Glu Ser Gly Gly Arg Cys Gly Pro Cys Pro Ala Gly Phe Thr Gly Asn	
110 115 120	

FIG. 4A

5/9

GGC TCG CAC TGC ACC GAC CTC GAT GGT GGC TGG AGC CAC TGG TCC CCG	436
Gly Ser His Cys Thr Asp Val Asp Gly Gly Trp Ser His Trp Ser Pro	
125 130 135	
TGG TCA TCT TGT TCT GTG ACA TGT GGT GAT GGT GTG ATC ACA AGG ATC	464
Trp Ser Ser Cys Ser Val Thr Cys Gly Asp Gly Val Ile Thr Arg Ile	
140 145 150	
CGG CTC TGC AAC TCT CCC AGC CCC CAG ATG AAC GGG AAA CCC TGT GAA	532
Arg Leu Cys Asn Ser Pro Ser Pro Gln Met Asn Gly Lys Pro Cys Glu	
155 160 165	
GGC GAA GCG CGG GAG ACC AAA GCC TGC AAG AAA GAC GCC TGC CCC ATC	580
Gly Glu Ala Arg Glu Thr Lys Ala Cys Lys Lys Asp Ala Cys Pro Ile	
170 175 180 185	
AAT GGA GGC TGG GGT CCT TGG TCA CCA TGG GAC ATC TGT TCT GTC ACC	628
Asn Gly Gly Trp Gly Pro Trp Ser Pro Trp Asp Ile Cys Ser Val Thr	
190 195 200	
TGT GGA GGA GGG GTA CAG AAA CGT AGT CGT CTC TGC AAC AAC CCC ACA	676
Cys Gly Gly Gly Val Gln Lys Arg Ser Arg Leu Cys Asn Asn Pro Thr	
205 210 215	
CCC CAG TTT GGA GGC AAG GAC TGC GTT GGT GAT GTA ACA GAA AAC CAG	724
Pro Gln Phe Gly Gly Lys Asp Cys Val Gly Asp Val Thr Glu Asn Gln	
220 225 230	
ATC TGC AAC AAG CAG GAC TGT CCA ATC TAG A	755
Ile Cys Asn Lys Gln Asp Cys Pro Ile *	
235 240	

FIG. 4B

6/9

CAGCAGCCAG	CTCCCCGCCA	CCGCC	ATG	GTC	CCC	GAC	ACC	GCC	TGC	GTT	CTT	52				
			Met	Val	Pro	Asp	Thr	Ala	Cys	Val	Leu					
			1				5									
CTG	CTC	ACC	CTG	GCT	GCC	CTC	GGC	GCG	TCC	GGA	CAG	GGC	CAG	AGC	CCG	100
Leu	Leu	Thr	Leu	Ala	Ala	Leu	Gly	Ala	Ser	Gly	Gln	Gly	Gln	Ser	Pro	
10				15					20						25	
TTG	GGC	TCA	GAC	CTG	GGC	CCG	CAG	ATG	CTT	CGG	GAA	CTG	CAG	GAA	ACC	148
Leu	Gly	Ser	Asp	Leu	Gly	Pro	Gln	Met	Leu	Arg	Glu	Leu	Gln	Glu	Thr	
				30				35						40		
AAC	GCG	GCG	CTG	CAG	GAC	GTG	CGG	GAC	TGG	CTG	CGG	CAG	CAG	GTC	AGG	196
Asn	Ala	Ala	Leu	Gln	Asp	Val	Arg	Asp	Trp	Leu	Arg	Gln	Gln	Val	Arg	
			45					50						55		
GAG	ATC	ACG	TTC	CTG	AAA	AAC	ACG	GTG	ATG	GAG	TGT	GAC	GCG	TGC	GGG	244
Glu	Ile	Thr	Phe	Leu	Lys	Asn	Thr	Val	Met	Glu	Cys	Asp	Ala	Cys	Gly	
		60					65					70				
ATG	CAG	CAG	TCA	GTA	CGC	ACC	GGC	CTA	CCC	AGC	GTG	CGG	CCC	CTG	CTC	292
Met	Gln	Gln	Ser	Val	Arg	Thr	Gly	Leu	Pro	Ser	Val	Arg	Pro	Leu	Leu	
	75					80					85					
CAC	TGC	GCG	CCC	GGC	TTC	TGC	TTC	CCC	GGC	GTG	GCC	TGC	ATC	CAG	ACG	340
His	Cys	Ala	Pro	Gly	Phe	Cys	Phe	Pro	Gly	Val	Ala	Cys	Ile	Gln	Thr	
90					95				100						105	
GAG	AGC	GGC	GGC	CGC	TGC	GGC	CCC	TGC	CCC	GCG	GGC	TTC	ACG	GGC	AAC	388
Glu	Ser	Gly	Gly	Arg	Cys	Gly	Pro	Cys	Pro	Ala	Gly	Phe	Thr	Gly	Asn	
				110				115						120		
GGC	TGC	CAC	TGC	ACC	GAC	GTC	GAG	GAG	GGC	TGG	TCT	CCG	TGG	GCA	GAG	436
Gly	Ser	His	Cys	Thr	Asp	Val	Glu	Glu	Gly	Trp	Ser	Pro	Trp	Ala	Glu	
			125				130						135			
TGG	ACC	CAG	TGC	TCC	GTG	ACG	TGT	GGC	TCT	GGG	ACC	CAG	CAG	AGA	GGC	484
Trp	Thr	Gln	Cys	Ser	Val	Thr	Cys	Gly	Ser	Gly	Thr	Gln	Gln	Arg	Gly	
	140						145					150				

FIG. 5A

7/9



CGG TCC TGT GAC GTC ACC AGC AAC ACC TGC TTG GGG CCC TCG ATC CAG	532
Arg Ser Cys Asp Val Thr Ser Asn Thr Cys Leu Gly Pro Ser Ile Gln	
155 160 165	
ACA CGG GCT TGC AGT CTG AGC AAG TGT GAC ACC CGC ATC CGG CAG GAC	580
Thr Arg Ala Cys Ser Leu Ser Lys Cys Asp Thr Arg Ile Arg Gln Asp	
170 175 180 185	
GGC GGC TGG AGC CAC TGG TCA CCT TGG TCT TCA TGC TCT GTG ACC TGT	628
Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser Val Thr Cys	
190 195 200	
GGA GTT GGC AAT ATC ACA CGC ATC CGT CTC TGC AAC TCC CCA GTG CCC	676
Gly Val Gly Asn Ile Thr Arg Ile Arg Leu Cys Asn Ser Pro Val Pro	
205 210 215	
CAG ATG GGG GGC AAG AAT TGC AAA GGG AGT GGC CGG GAG ACC AAA GCC	724
Gln Met Gly Gly Lys Asn Cys Lys Gly Ser Gly Arg Glu Thr Lys Ala	
220 225 230	
TGC CAG GGC GCC CCA TGC CCA ATC GAT GGC CGC TGG AGC CCC TGG TCC	772
Cys Gln Gly Ala Pro Cys Pro Ile Asp Gly Arg Trp Ser Pro Trp Ser	
235 240 245	
CCG TGG TCG GCC TGC ACT GTC ACC TGT GCC GGT GGG ATC CGG GAG CGC	820
Pro Trp Ser Ala Cys Thr Val Thr Cys Ala Gly Gly Ile Arg Glu Arg	
250 255 260 265	
ACC CGG GTC TGC AAC AGC CCT GAG CCT CAG TAC GGA GGG AAG GCC TGC	868
Thr Arg Val Cys Asn Ser Pro Glu Pro Gln Tyr Gly Gly Lys Ala Cys	
270 275 280	
GTG GGG GAT GTG CAG GAG CST CAG ATG TGC AAC AAG AGG AGC TGC CCC	916
Val Gly Asp Val Gln Glu Arg Gln Met Cys Asn Lys Arg Ser Cys Pro	
285 290 295	
GTG TCT AGA	925
Val Ser Arg	

FIG. 5B

COMP/TSP-1




8/9

COMP/ENDOSTATIN



COMP/TSP-1P

COMP/TSP-2



pentamerization domain of human COMP



type 2 repeat of human COMP




second and third type 1 repeats of TSP-1



all three type 1 repeats of TSP-1 or-2



procollagen homology region



endostatin

FIG. 6

SUBSTITUTE SHEET (RULE 26)

9/9




FIG. 7

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/02482

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/52 C07K14/78 C07K19/00 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BIOSIS, MEDLINE, SCISEARCH, BIOTECHNOLOGY ABS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PANETTI TS ET AL: "Interaction of recombinant procollagen and properdin modules of thrombospondin-1 with heparin and fibrinogen/fibrin." JOURNAL OF BIOLOGICAL CHEMISTRY, JAN 1 1999, 274 (1) P430-7, XP002140107	1,12,13, 25
A	UNITED STATES abstract; figure 2B	2-5,10, 11, 14-24, 26-28
	---	-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

21 September 2000

Date of mailing of the international search report

18. 10. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	QABAR AZIZ N ET AL: "A chimeric murine TSP3/human TSP1 is a pentamer with abolished antiangiogenic activity." ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY 97;NEW ORLEANS, LOUISIANA, USA; APRIL 6-9, 1997, vol. 11, no. 3, 1997, page A63 XP000914726 FASEB Journal 1997 ISSN: 0892-6638 the whole document	1,12,13, 25
A	WO 98 18943 A (CIBA GEIGY AG ;KAJAVA ANDREY (CH); UNIV LAUSANNE (CH); CRAMER RET) 7 May 1998 (1998-05-07) abstract; claims 1-32	1-5, 10-28,33
A	WO 98 39418 A (ARIAD GENE THERAPEUTICS INC ;GILMAN MICHAEL Z (US)) 11 September 1998 (1998-09-11) claims 1-5	1-5, 10-28,33
A	WO 93 16716 A (UNIV NORTHWESTERN) 2 September 1993 (1993-09-02) claims 1-11; figures SEQ.ID.1,2	1-5, 10-28,33
A	KUNO ET AL: "Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene" JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 1, 3 January 1997 (1997-01-03), pages 556-562, XP002076038 ISSN: 0021-9258 abstract; figures 5,6	1-5, 10-28,33
Y	WO 96 37621 A (HOESS ADOLF ;PACK PETER (DE); MORPHOSYS PROTEINOPTIMIERUNG (DE)) 28 November 1996 (1996-11-28) claims 1,4-7	6-9, 29-32
Y	EP 0 407 122 A (REPLIGEN CORP) 9 January 1991 (1991-01-09) claims 1-23	9,32
Y	WO 98 54217 A (CHILDRENS MEDICAL CENTER) 3 December 1998 (1998-12-03) abstract; claims 1-15	7,30

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/02482

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 51323 A (STRUMAN INGRID ;MARTIAL JOSEPH A (BE); TAYLOR ROBERT (US); UNIV CA) 19 November 1998 (1998-11-19) abstract; claims 1-26 ---	8,31
Y	NGUYEN JOSEPHINE T ET AL: "Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy." CANCER RESEARCH, vol. 58, no. 24, 15 December 1998 (1998-12-15), pages 5673-5677, XP000857408 ISSN: 0008-5472 the whole document ---	6,29
A	TOMSCHY ANDREA ET AL: "Homophilic adhesion of E-cadherin occurs by a co-operative two-step interaction of N-terminal domains." EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 15, no. 14, 1996, pages 3507-3514, XP002147181 ISSN: 0261-4189 the whole document ---	6-9, 29-32
A	TERSKIKH ALEXEY V ET AL: "'Peptabody": A new type of high avidity binding protein." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 5, 1997, pages 1663-1668, XP002147182 1997 ISSN: 0027-8424 the whole document ---	6-9, 29-32
A	NEWTON GAIL ET AL: "Characterization of human and mouse cartilage oligomeric matrix protein." GENOMICS, vol. 24, no. 3, 1994, pages 435-439, XP002147953 ISSN: 0888-7543 the whole document ---	34-50
A	O'ROURKE KM ET AL: "Thrombospondin 1 and thrombospondin 2 are expressed as both homo- and heterotrimers." JOURNAL OF BIOLOGICAL CHEMISTRY, DEC 15 1992, 267 (35) P24921-4, XP002147183 UNITED STATES the whole document -----	34-50

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/02482

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 51-53 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 51-53 partially and 1-5,10-28 ,33

TSP-1 chimeric protein constructs, corresponding nucleic acids ,vectors ,host cells , method of producing chimeric proteins

2. Claims: 51-53 partially and 34-50

TSP-2 chimeric protein constructs, corresponding nucleic acids ,vectors ,host cells ,method of producing chimeric proteins

3. Claims: 51-53 partially and 6-9, 29-32

COMP chimeric protein constructs, not provided in the first and second invention of present application , corresponding nucleic acids ,vectors ,host cells , method of producing chimeric proteins

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/02482

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9818943	A	07-05-1998	AU 6909298 A		22-05-1998
			EP 0938571 A		01-09-1999
WO 9839418	A	11-09-1998	AU 6692298 A		22-09-1998
WO 9316716	A	02-09-1993	NONE		
WO 9637621	A	28-11-1996	CA 2222055 A		28-11-1996
			EP 0827544 A		11-03-1998
			JP 11508126 T		21-07-1999
EP 0407122	A	09-01-1991	US 5112946 A		12-05-1992
			AT 143698 T		15-10-1996
			CA 2019086 A		06-01-1991
			DE 69028739 D		07-11-1996
			DE 69028739 T		13-02-1997
			DK 407122 T		17-02-1997
			EP 0723015 A		24-07-1996
			ES 2092493 T		01-12-1996
			GR 3021658 T		28-02-1997
			JP 3063297 A		19-03-1991
WO 9854217	A	03-12-1998	US 5945403 A		31-08-1999
			AU 7704998 A		30-12-1998
			EP 0996632 A		03-05-2000
WO 9851323	A	19-11-1998	AU 7383298 A		08-12-1998